Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants

ABSTRACT

The present invention relates to compositions and methods for preparing poly-unsaturated long chain fatty acids in plants, plant parts and plant cells, such as leaves, roots, fruits and seeds. Nucleic acid sequences and constructs encoding fatty acid desaturases, including  DELTA 5-desaturases,  DELTA 6-desaturases and  DELTA 12-desaturases, are used to generate transgenic plants, plant parts and cells which contain and express one or more transgenes encoding one or more desaturases. Expression of the desaturases with different substrate specificities in the plant system permit the large scale production of poly-unsaturated long chain fatty acids such as docosahexaenoic acid, eicosapentaenoic acid,  alpha -linoleic acid, gamma-linolenic acid, arachidonic acid and the like for modification of the fatty acid profile of plants, plant parts and tissues. Manipulation of the fatty acid profiles allows for the production of commercial quantities of novel plant oils and products.

FIELD OF THE INVENTION

This invention relates to modulating levels of enzymes and/or enzyme components capable of altering the production of long chain poly-unsaturated fatty acids (PUFAs) in a host plant. The invention is exemplified by the production of PUFAs in plants.

BACKGROUND

Two main families of poly-unsaturated fatty acids (PUFAs) are the ω3 fatty acids, exemplified by arachidonic acid, and the ω6 fatty acids, exemplified by eicosapentaenoic acid. PUFAs are important components of the plasma membrane of the cell, where they may be found in such forms as phospholipids and triglycerides. PUFAs also serve as precursors to other molecules of importance in human beings and animals, including the prostacyclins, leukotrienes and prostaglandins. PUFAs are necessary for proper development, particularly in the developing infant brain, and for tissue formation and repair.

Four major long chain PUFAs of importance include docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are primarily found in different types of fish oil, gamma-linolenic acid (GLA), which is found in the seeds of a number of plants, including evening primrose (Oenothera biennis), borage (Borago officinalis) and black currants (Ribes nigrum), and stearidonic acid (SDA), which is found in marine oils and plant seeds. Both GLA and another important long chain PUFA, arachidonic acid (ARA), are found in filamentous fungi. ARA can be purified from animal tissues including liver and adrenal gland.

For DHA, a number of sources exist for commercial production including a variety of marine organisms, oils obtained from cold water marine fish, and egg yolk fractions. For ARA, microorganisms including the genera Mortierella, Entomophthora, Phytium and Porphyridium can be used for commercial production. Commercial sources of SDA include the genera Trichodesma and Echium. Commercial sources of GLA include evening primrose, black currants and borage. However, there are several disadvantages associated with commercial production of PUFAs from natural sources. Natural sources of PUFAs, such as animals and plants, tend to have highly heterogeneous oil compositions. The oils obtained from these sources therefore can require extensive purification to separate out one or more desired PUFAs or to produce an oil which is enriched in one or more PUFA. Natural sources also are subject to uncontrollable fluctuations in availability. Fish stocks may undergo natural variation or may be depleted by overfishing. Fish oils have unpleasant tastes and odors, which may be impossible to economically separate from the desired product, and can render such products unacceptable as food supplements. Animal oils, and particularly fish oils, can accumulate environmental pollutants. Weather and disease can cause fluctuation in yields from both fish and plant sources. Cropland available for production of alternate oil-producing crops is subject to competition from the steady expansion of human populations and the associated increased need for food production on the remaining arable land. Crops which do produce PUFAs, such as borage, have not been adapted to commercial growth and may not perform well in monoculture. Growth of such crops is thus not economically competitive where more profitable and better established crops can be grown. Large scale fermentation of organisms such as Mortierella is also expensive. Natural animal tissues contain low amounts of ARA and are difficult to process. Microorganisms such as Porphyridium and Mortierella are difficult to cultivate on a commercial scale.

Dietary supplements and pharmaceutical formulations containing PUFAs can retain the disadvantages of the PUFA source. Supplements such as fish oil capsules can contain low levels of the particular desired component and thus require large dosages. High dosages result in ingestion of high levels of undesired components, including contaminants. Care must be taken in providing fatty acid supplements, as overaddition may result in suppression of endogenous biosynthetic pathways and lead to competition with other necessary fatty acids in various lipid fractions in vivo, leading to undesirable results. For example, Eskimos having a diet high in ω3 fatty acids have an increased tendency to bleed (U.S. Pat. No. 4,874,603). Unpleasant tastes and odors of the supplements can make such regimens undesirable, and may inhibit compliance by the patient.

A number of enzymes are involved in PUFA biosynthesis. Linoleic acid (LA, 18:2 Δ⁹,12) is produced from oleic acid (18:1 Δ⁹) by a Δ12-desaturase. GLA (18:3 Δ⁶,9,12) is produced from linoleic acid (LA, 18:2 Δ⁹,12) by a Δ6-desaturase. ARA (20:4 Δ⁵,8,11,14) production from DGLA (20:3 Δ⁸,11,14) is catalyzed by a Δ5-desaturase. However, animals cannot desaturate beyond the Δ⁹ position and therefore cannot convert oleic acid (18:1 Δ⁹) into linoleic acid (18:2 Δ⁹,12). Likewise, α-linolenic acid (ALA, 18:3 Δ⁹,12,15) cannot be synthesized by mammals. Other eukaryotes, including fungi and plants, have enzymes which desaturate at positions Δ¹² and Δ¹⁵. The major poly-unsaturated fatty acids of animals therefore are either derived from diet and/or from desaturation and elongation of linoleic acid (18:2 Δ⁹,12) or ∝-linolenic acid (18:3 Δ⁹,12,15).

Poly-unsaturated fatty acids are considered to be useful for nutritional, pharmaceutical, industrial, and other purposes. An expansive supply of poly-unsaturated fatty acids from natural sources and from chemical synthesis are not sufficient for commercial needs. Therefore it is of interest to obtain genetic material involved in PUFA biosynthesis from species that naturally produce these fatty acids and to express the isolated material alone or in combination in a heterologous system which can be manipulated to allow production of commercial quantities of PUFAS.

Relevant Literature

Production of gamma-linolenic acid by a Δ6-desaturase is described in U.S. Pat. No. 5,552,306 and U.S. Pat. No. 5,614,393. Production of 8,11-eicosadienoic acid using Mortierella alpina is disclosed in U.S. Pat. No. 5,376,541. Production of docosahexaenoic acid by dinoflagellates is described in U.S. Pat. No. 5,407,957. Cloning of a Δ6-desaturase from borage is described in PCT publication WO 96/21022. Cloning of Δ9-desaturases is described in the published patent applications PCT WO 91/13972, EP 0 550 162 A1, EP 0 561 569 A2, EP 0 644 263 A2, and EP 0 736 598 A1, and in U.S. Pat. No. 5,057,419. Cloning of Δ12-desaturases from various organisms is described in PCT publication WO 94/11516 and U.S. Pat. No. 5,443,974. Cloning of Δ15-desaturases from various organisms is described in PCT publication WO 93/11245. A Δ6 palmitoyl-acyl carrier protein desaturase from Thumbergia alata and its expression in E. coli is described in U.S. Pat. No. 5,614,400. Expression of a soybean stearyl-ACP desaturase in transgenic soybean embryos using a 35S promoter is disclosed in U.S. Pat. No. 5,443,974.

SUMMARY OF THE INVENTION

Novel compositions and methods are provided for preparation of poly-unsaturated long chain fatty acids and desaturases in plants and plant cells. The methods involve growing a host plant cell of interest transformed with an expression cassette functional in a host plant cell, the expression cassette comprising a transcriptional and translational initiation regulatory region, joined in reading frame 5' to a DNA sequence encoding a desaturase polypeptide capable of modulating the production of PUFAs. Expression of the desaturase polypeptide provides for an alteration in the PUFA profile of host plant cells as a result of altered concentrations of enzymes involved in PUFA biosynthesis. Of particular interest is the selective control of PUFA production in plant tissues and/or plant parts such as leaves, roots, fruits and seeds. The invention finds use for example in the large scale production of DHA, EPA, ALA, and GLA and for modification of the fatty acid profile of edible plant tissues and/or plant parts.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows possible pathways for the synthesis of arachidonic acid (20:4 Δ⁵,8,11,14) and stearidonic acid (18:4 Δ⁶,9,12,15) from palmitic acid (C₁₆) from a variety of organisms, including algae, Mortierella and humans. These PUFAs can serve as precursors to other molecules important for humans and other animals, including prostacyclins, leukotrienes, and prostaglandins, some of which are shown.

FIG. 2 shows possible pathways for production of PUFAs in addition to ARA, including EPA and DHA, again compiled from a variety of organisms.

FIGS. 3A-E shows the DNA sequence of (SEQ ID NO:1) the Mortierella alpina Δ6 desaturase and the deduced amino acid sequence.

FIG. 4 shows an alignment of the Mortierella alpina Δ6 partial desaturase amino acid sequence (SEQ ID NO:2) with other Δ6 desaturases and related sequences (SEQ ID NO:7,8,9,10,11,12).

FIGS. 5A-D shows the DNA sequence (SEQ ID NO:3) of the Mortierella alpina Δ12 desaturase and the deduced amino acid sequence (SEQ ID NO:4).

FIG. 6 shows the deduced amino acid sequence (SEQ ID NO:13) of the PCR fragment (see Example 1).

FIG. 7 shows alignments of the amino acid sequence of the Δ5 desaturase (SEQ ID NO:15) with Δ6 desaturases and related sequences (SEQ ID NO:14,15,16,17).

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO:1 shows the DNA sequence of the Mortierella alpina Δ6 desaturase.

SEQ ID NO:2 shows the amino acid sequence of the Mortierella alpina Δ6 desaturase.

SEQ ID NO:3 shows the DNA sequence of the Mortierella alpina Δ12 desaturase.

SEQ ID NO:4 shows the amino acid sequence of the Mortierella alpina Δ12 desaturase.

SEQ ID NO:5 shows the amino acid sequence of the Mortierella alpina Δ5 desaturase.

SEQ ID NO:6 shows the partial amino acid sequence Mortierella alpina Δ6 desaturase.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In accordance with the subject invention, novel DNA sequences, DNA constructs, methods and compositions are provided which permit modification of the poly-unsaturated long chain fatty acid content of plant cells. Plant cells are transformed with an expression cassette comprising a DNA encoding a polypeptide capable of increasing the amount of one or more PUFA in a plant cell. Desirably, integration constructs may be prepared which provide for integration of the expression cassette into the genome of a host cell. Host cells are manipulated to express an antisense DNA or a DNA encoding a polypeptide(s) that has desaturase activity. By "desaturase" is intended a polypeptide which can desaturate one or more fatty acids to produce a mono- or poly-unsaturated fatty acid or precursor thereof of interest. By "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification, for example, glycosylation or phosphorylation. The substrate(s) for the expressed enzyme may be produced by the host cell or may be exogenously supplied.

To achieve expression in a host cell, the transformed DNA is operably associated with transcriptional and translational initiation and termination regulatory regions that are functional in the host cell. Constructs comprising the gene to be expressed can provide for integration into the genome of the host cell or can autonomously replicate in the host cell. For production of linoleic acid (LA), the expression cassettes generally used include a cassette which provides for Δ12 desaturase activity, particularly in a host cell which produces or can take up oleic acid. For production of ALA, the expression cassettes generally used include a cassette which provides for Δ15 or ω3 desaturase activity, particularly in a host cell which produces or can take up LA. For production of GLA or SDA, the expression cassettes generally used include a cassette which provides for Δ6 desaturase activity, particularly in a host cell which produces or can take up LA or ALA, respectively. Production of ω6-type unsaturated fatty acids, such as LA or GLA, is favored in a plant capable of producing ALA by inhibiting the activity of a Δ15 or ω3 type desaturase; this is accomplished by providing an expression cassette for an antisense Δ15 or ω3 transcript, or by disrupting a Δ15 or ω3 desaturase gene. Similarly, production of LA or ALA is favored in a plant having Δ6 desaturase activity by providing an expression cassette for an antisense Δ6 transcript, or by disrupting a Δ6 desaturase gene. Production of oleic acid likewise is favored in a plant having Δ12 desaturase activity by providing an expression cassette for an antisense Δ12 transcript, or by disrupting a Δ12 desaturase gene. For production of ARA, the expression cassette generally used provides for Δ5 desaturase activity, particularly in a host cell which produces or can take up DGLA. Production of ω6-type unsaturated fatty acids, such as ARA, is favored in a plant capable of producing ALA by inhibiting the activity of a Δ15 or ω3 type desaturase; this is accomplished by providing an expression cassette for an antisense Δ15 or ω3 transcript, or by disrupting a Δ15 or ω3 desaturase gene.

Transgenic plant production of PUFAs offers several advantages over purification from natural sources such as fish or plants. Production of fatty acids from recombinant plants provides the ability to alter the naturally occurring plant fatty acid profile by providing new synthetic pathways in the host or by suppressing undesired pathways, thereby increasing levels of desired PUFAs, or conjugated forms thereof, and decreasing levels of undesired PUFAs. Production of fatty acids in transgenic plants also offers the advantage that expression of desaturase genes in particular tissues and/or plant parts means that greatly increased levels of desired PUFAs in those tissues and/or parts can be achieved, making recovery from those tissues more economical. For example, the desired PUFAs can be expressed in seed; methods of isolating seed oils are well established. In addition to providing a source for purification of desired PUFAs, seed oil components can be manipulated through expression of desaturase genes, either alone or in combination with other genes such as elongases, to provide seed oils having a particular PUFA profile in concentrated form. The concentrated seed oils then can be added to animal milks and/or synthetic or semisythetic milks to serve as infant formulas where human nursing is impossible or undesired, or in cases of malnourishment or disease in both adults and infants.

For production of PUFAs, depending upon the host cell, the availability of substrate, and the desired end product(s), several polypeptides, particularly desaturases, are of interest including those polypeptides which catalyze the conversion of stearic acid to oleic acid, LA to GLA, of ALA to SDA, of oleic acid to LA, or of LA to ALA, which includes enzymes which desaturate at the Δ6, Δ9, Δ12, Δ15 or ω3 positions. Considerations for choosing a specific polypeptide having desaturase activity include the pH optimum of the polypeptide, whether the polypeptide is a rate limiting enzyme or a component thereof, whether the desaturase used is essential for synthesis of a desired poly-unsaturated fatty acid, and/or co-factors required by the polypeptide. The expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell. For example, the polypeptide may have to compete for substrate with other enzymes in the host cell. Analyses of the K_(m) and specific activity of the polypeptide in question therefore are considered in determining the suitability of a given polypeptide for modifying PUFA production in a given host cell. The polypeptide used in a particular situation therefore is one which can function under the conditions present in the intended host cell but otherwise can be any polypeptide having desaturase activity which has the desired characteristic of being capable of modifying the relative production of a desired PUFA. A scheme for the synthesis of arachidonic acid (20:4 Δ⁵,8,11,14) from palmitic acid (C₁₆) is shown in FIG. 1. A key enzyme in this pathway is a Δ5-desaturase which converts DH-γ-linolenic acid (DGLA, eicosatrienoic acid) to ARA. Conversion of a-linolenic acid (ALA) to stearidonic acid by a Δ6-desaturase is also shown. Production of PUFAs in addition to ARA, including EPA and DHA is shown in FIG. 2. A key enzyme in the synthesis of arachidonic acid (20:4 Δ⁵,8,11,14) from stearic acid (C₁₈) is a Δ6-desaturase which converts the linoleic acid into γ-linolenic acid. Conversion of α-linolenic acid (ALA) to stearidonic acid by a Δ6-desaturase also is shown. For production of ARA, the DNA sequence used encodes a polypeptide having Δ5 desaturase activity. In particular instances, this can be coupled with an expression cassette which provides for production of a polypeptide having Δ6 desaturase activity and, optionally, a transcription cassette providing for production of antisense sequences to a Δ15 transcription product. The choice of combination of cassettes used depends in part on the PUFA profile of the host cell. Where the host cell Δ5-desaturase activity is limiting, overexpression of Δ5 desaturase alone generally will be sufficient to provide for enhanced ARA production.

As sources of polypeptides having desaturase activity and oligonucleotides encoding such polypeptides are organisms which produce a desired poly-unsaturated fatty acid. As an example, microorganisms having an ability to produce ARA can be used as a source of Δ5-desaturase genes; microorganisms which GLA or SDA can be used as a source of Δ6-desaturase and/or Δ12-desaturase genes. Such microorganisms include, for example, those belonging to the genera Mortierella, Conidiobolus, Pythium, Phytophathora, Penicillium, Porphyridium, Coidosporium, Mucor, Fusarium, Aspergillus, Rhodotorula, and Entomophthora. Within the genus Porphyridium, of particular interest is Porphyridium cruentum. Within the genus Mortierella, of particular interest are Mortierella elongata, Mortierella exigua, Mortierella hygrophila, Mortierella ramanniana, var. angulispora, and Mortierella alpina. Within the genus Mucor, of particular interest are Mucor circinelloides and Mucor javanicus.

DNAs encoding desired desaturases can be identified in a variety of ways. As an example, a source of the desired desaturase, for example genomic or cDNA libraries from Mortierella, is screened with detectable enzymatically- or chemically-synthesized probes, which can be made from DNA, RNA, or non-naturally occurring nucleotides, or mixtures thereof. Probes may be enzymatically synthesized from DNAs of known desaturases for normal or reduced-stringency hybridization methods. Oligonucleotide probes also can be used to screen sources and can be based on sequences of known desaturases, including sequences conserved among known desaturases, or on peptide sequences obtained from the desired purified protein. Oligonucleotide probes based on amino acid sequences can be degenerate to encompass the degeneracy of the genetic code, or can be biased in favor of the preferred codons of the source organism. Oligonucleotides also can be used as primers for PCR from reverse transcribed mRNA from a known or suspected source; the PCR product can be the full length cDNA or can be used to generate a probe to obtain the desired full length cDNA. Alternatively, a desired protein can be entirely sequenced and total synthesis of a DNA encoding that polypeptide performed.

Once the desired genomic or cDNA has been isolated, it can be sequenced by known methods. It is recognized in the art that such methods are subject to errors, such that multiple sequencing of the same region is routine and is still expected to lead to measurable rates of mistakes in the resulting deduced sequence, particularly in regions having repeated domains, extensive secondary structure, or unusual base compositions, such as regions with high GC base content. When discrepancies arise, resequencing can be done and can employ special methods. Special methods can include altering sequencing conditions by using: different temperatures; different enzymes; proteins which alter the ability of oligonucleotides to form higher order structures; altered nucleotides such as ITP or methylated dGTP; different gel compositions, for example adding formamide; different primers or primers located at different distances from the problem region; or different templates such as single stranded DNAs. Sequencing of MRNA can also be employed.

For the most part, some or all of the coding sequence for the polypeptide having desaturase activity is from a natural source. In some situations, however, it is desirable to modify all or a portion of the codons, for example, to enhance expression, by employing host preferred codons. Host preferred codons can be determined from the codons of highest frequency in the proteins expressed in the largest amount in a particular host species of interest. Thus, the coding sequence for a polypeptide having desaturase activity can be synthesized in whole or in part. All or portions of the DNA also can be synthesized to remove any destabilizing sequences or regions of secondary structure which would be present in the transcribed mRNA. All or portions of the DNA also can be synthesized to alter the base composition to one more preferable in the desired host cell. Methods for synthesizing sequences and bringing sequences together are well established in the literature. In vitro mutagenesis and selection, site-directed mutagenesis, or other means can be employed to obtain mutations of naturally occurring desaturase genes to produce a polypeptide having desaturase activity in vivo with more desirable physical and kinetic parameters for function in the host cell, such as a longer half-life or a higher rate of production of a desired polyunsaturated fatty acid.

Desirable cDNAs have less than 60% A+T composition, preferably less than 50% A+T composition. On a localized scale of a sliding window of 20 base pairs, it is preferable that there are no localized regions of the cDNA with greater than 75% A+T composition; with a window of 60 base pairs, it is preferable that there are no localized regions of the cDNA with greater than 50%.

Of particular interest are the Mortierella alpina Δ5-desaturase, Δ6-desaturase and Δ12-desaturase. The Δ5-desaturase (SEQ ID NO:5) has 446 amino acids; the amino acid sequence is shown in FIG. 6. The gene encoding the Mortierella alpina Δ5-desaturase can be expressed in transgenic microorganisms to effect greater synthesis of ARA from DGLA. Other DNAs which are substantially identical in sequence to the Mortierella alpina Δ5-desaturase DNA, or which encode polypeptides which are substantially identical in sequence to the Mortierella alpina Δ5-desaturase polypeptide, also can be used. The Mortierella alpina Δ6-desaturase, has 457 amino acids and a predicted molecular weight of 51.8 kD; the amino acid sequence is shown in FIGS. 34-E. The gene encoding the Mortierella alpina Δ6-desaturase can be expressed in transgenic plants or animals to effect greater synthesis of GLA from linoleic acid or of stearidonic acid (SDA) from ALA. Other DNAs which are substantially identical in sequence to the Mortierella alpina Δ6-desaturase DNA, or which encode polypeptides which are substantially identical in sequence to the Mortierella alpina Δ6-desaturase polypeptide, also can be used.

The Mortierella alpina Δ12-desaturase has the amino acid sequence shown in FIGS. 5A-D. The gene encoding the Mortierella alpina Δ12-desaturase can be expressed in transgenic plants to effect greater synthesis of LA from oleic acid. Other DNAs which are substantially identical to the Mortierella alpina Δ12-desaturase DNA, or which encode polypeptides which are substantially identical to the Mortierella alpina Δ12-desaturase polypeptide, also can be used. By substantially identical in sequence is intended an amino acid sequence or nucleic acid sequence exhibiting in order of increasing preference at least 60%, 80%, 90% or 95% homology to the Mortierella alpina Δ5-desaturase amino acid sequence or nucleic acid sequence encoding the amino acid sequence. For polypeptides, the length of comparison sequences generally is at least 16 amino acids, preferably at least 20 amino acids, or most preferably 35 amino acids. For nucleic acids, the length of comparison sequences generally is at least 50 nucleotides, preferably at least 60 nucleotides, and more preferably at least 75 nucleotides, and most preferably, 110 nucleotides. Homology typically is measured using sequence analysis software, for example, the Sequence Analysis software package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, MEGAlign (DNAStar, Inc., 1228 S. Park St., Madison, Wis. 53715), and MacVector (Oxford Molecular Group, 2105 S. Bascom Avenue, Suite 200, Campbell, Calif. 95008). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid, glutamic acid, asparagine, and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Substitutions may also be made on the basis of conserved hydrophobicity or hydrophilicity (Kyte and Doolittle, J. Mol. Biol. 157: 105-132, 1982), or on the basis of the ability to assume similar polypeptide secondary structure (Chou and Fasman, Adv. Enzymol. 47: 45-148, 1978).

Encompassed by the present invention are related desaturases from the same or other organisms. Such related desaturases include variants of the disclosed Δ5-, Δ6- and Δ12-desaturases that occur naturally within the same or different species of Mortierella, as well as homologues of the disclosed Δ5-desaturase from other species and evolutionarily related protein having desaturase activity. Also included are desaturases which, although not substantially identical to the Mortierella alpina Δ5-desaturase, desaturate a fatty acid molecule at carbon 5, 6, or 12 respectively, from the carboxyl end of a fatty acid molecule. Related desaturases can be identified by their ability to function substantially the same as the disclosed desaturases; that is, are still able to effectively convert DGLA to ARA, LA to GLA, ALA to SDA or oleic acid to LA. Related desaturases also can be identified by screening sequence databases for sequences homologous to the disclosed desaturase, by hybridization of a probe based on the disclosed desaturase to a library constructed from the source organism, or by RT-PCR using mRNA from the source organism and primers based on the disclosed desaturase.

The regions of a desaturase polypeptide important for desaturase activity can be determined through routine mutagenesis, expression of the resulting mutant polypeptides and determination of their activities. Mutants may include deletions, insertions and point mutations, or combinations thereof. A typical functional analysis begins with deletion mutagenesis to determine the N- and C-terminal limits of the protein necessary for function, and then internal deletions, insertions or point mutants are made to further determine regions necessary for function. Other techniques such as cassette mutagenesis or total synthesis also can be used. Deletion mutagenesis is accomplished, for example, by using exonucleases to sequentially remove the 5' or 3' coding regions. Kits are available for such techniques. After deletion, the coding region is completed by ligating oligonucleotides containing start or stop codons to the deleted coding region after 5' or 3' deletion, respectively. Alternatively, oligonucleotides encoding start or stop codons are inserted into the coding region by a variety of methods including site-directed mutagenesis, mutagenic PCR or by ligation onto DNA digested at existing restriction sites. Internal deletions can similarly be made through a variety of methods including the use of existing restriction sites in the DNA, by use of mutagenic primers via site directed mutagenesis or mutagenic PCR. Insertions are made through methods such as linker-scanning mutagenesis, site-directed mutagenesis or mutagenic PCR. Point mutations are made through techniques such as site-directed mutagenesis or mutagenic PCR.

Chemical mutagenesis can also be used for identifying regions of a desaturase polypeptide important for activity. A mutated construct is expressed, and the ability of the resulting altered protein to function as a desaturase is assayed. Such structure-function analysis can determine which regions may be deleted, which regions tolerate insertions, and which point mutations allow the mutant protein to function in substantially the same way as the native desaturase. All such mutant proteins and nucleotide sequences encoding them are within the scope of the present invention.

Once the DNA encoding a desaturase polypeptide has been obtained, it is placed in a vector capable of replication in a host cell, or is propagated in vitro by means of techniques such as PCR or long PCR. Replicating vectors can include plasmids, phage, viruses, cosmids and the like. Desirable vectors include those useful for mutagenesis of the gene of interest or for expression of the gene of interest in host cells. The technique of long PCR has made in vitro propagation of large constructs possible, so that modifications to the gene of interest, such as mutagenesis or addition of expression signals, and propagation of the resulting constructs can occur entirely in vitro without the use of a replicating vector or a host cell.

For expression of a desaturase polypeptide, functional transcriptional and translational initiation and termination regions are operably linked to the DNA encoding the desaturase polypeptide. Transcriptional and translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, expression vectors, chemical synthesis, or from an endogenous locus in a host cell. Expression in a plant tissue and/or plant part presents certain efficiencies, particularly where the tissue or part is one which is easily harvested, such as seed, leaves, fruits, flowers, roots, etc. Expression can be targeted to that location within the plant by using specific regulatory sequences, such as those of U.S. Pat. No. 5,463,174, U.S. Pat. No. 4,943,674, U.S. Pat. No. 5,106,739, U.S. Pat. No. 5,175,095, U.S. Pat. No. 5,420,034, U.S. Pat. No. 5,188,958, and U.S. Pat. No. 5,589,379. Alternatively, the expressed protein can be an enzyme which produces a product which may be incorporated, either directly or upon further modifications, into a fluid fraction from the host plant. In the present case, expression of desaturase genes, or antisense desaturase transcripts, can alter the levels of specific PUFAs, or derivatives thereof, found in plant parts and/or plant tissues. The Δ5-desaturase polypeptide coding region is expressed either by itself or with other genes, in order to produce tissues and/or plant parts containing higher proportions of desired PUFAs or in which the PUFA composition more closely resembles that of human breast milk (Prieto et al., PCT publication WO 95/24494). The termination region can be derived from the 3' region of the gene from which the initiation region was obtained or from a different gene. A large number of termination regions are known to and have been found to be satisfactory in a variety of hosts from the same and different genera and species. The termination region usually is selected more as a matter of convenience rather than because of any particular property.

The choice of a host cell is influenced in part by the desired PUFA profile of the transgenic cell, and the native profile of the host cell. As an example, for production of linoleic acid from oleic acid, the DNA sequence used encodes a polypeptide having Δ12 desaturase activity, and for production of GLA from linoleic acid, the DNA sequence used encodes a polypeptide having Δ6 desaturase activity. Use of a host cell which expresses Δ12 desaturase activity and lacks or is depleted in Δ15 desaturase activity, can be used with an expression cassette which provides for overexpression of Δ6 desaturase alone generally is sufficient to provide for enhanced GLA production in the transgenic cell. Where the host cell expresses Δ9 desaturase activity, expression of both a Δ12- and a Δ6-desaturase can provide for enhanced GLA production. In particular instances where expression of Δ6 desaturase activity is coupled with expression of Δ12 desaturase activity, it is desirable that the host cell naturally have, or be mutated to have, low Δ15 desaturase activity. Alternatively, a host cell for Δ6 desaturase expression may have, or be mutated to have, high Δ12 desaturase activity.

Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can occur from introduced constructs which contain expression signals functional in the host cell, but which constructs do not replicate and rarely integrate in the host cell, or where the host cell is not proliferating. Transient expression also can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest, although such inducible systems frequently exhibit a low basal level of expression. Stable expression can be achieved by introduction of a construct that can integrate into the host genome or that autonomously replicates in the host cell. Stable expression of the gene of interest can be selected for through the use of a selectable marker located on or transfected with the expression construct, followed by selection for cells expressing the marker. When stable expression results from integration, integration of constructs can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

When increased expression of the desaturase polypeptide in the source plant is desired, several methods can be employed. Additional genes encoding the desaturase polypeptide can be introduced into the host organism. Expression from the native desaturase locus also can be increased through homologous recombination, for example by inserting a stronger promoter into the host genome to cause increased expression, by removing destabilizing sequences from either the mRNA or the encoded protein by deleting that information from the host genome, or by adding stabilizing sequences to the mRNA (see U.S. Pat. No. 4,910,141 and U.S. Pat. No. 5,500,365.)

When it is desirable to express more than one different gene, appropriate regulatory regions and expression methods, introduced genes can be propagated in the host cell through use of replicating vectors or by integration into the host genome. Where two or more genes are expressed from separate replicating vectors, it is desirable that each vector has a different means of replication. Each introduced construct, whether integrated or not, should have a different means of selection and should lack homology to the other constructs to maintain stable expression and prevent reassortment of elements among constructs. Judicious choices of regulatory regions, selection means and method of propagation of the introduced construct can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.

Constructs comprising the gene of interest may be introduced into a host cell by standard techniques. These techniques include transfection, infection, biolistic impact, electroporation, microinjection, scraping, or any other method which introduces the gene of interest into the host cell (see U.S. Pat. No. 4,743,548, U.S. Pat. No. 4,795,855, U.S. Pat. No. 5,068,193, U.S. Pat. No. 5,188,958, U.S. Pat. No. 5,463,174, U.S. Pat. No. 5,565,346 and U.S. Pat. No. 5,565,347). For convenience, a host cell which has been manipulated by any method to take up a DNA sequence or construct will be referred to as "transformed" or "recombinant" herein. The subject host will have at least have one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified, or is present on an extrachromosomal element having multiple copy numbers.

The transformed host cell can be identified by selection for a marker contained on the introduced construct. Alternatively, a separate marker construct may be introduced with the desired construct, as many transformation techniques introduce many DNA molecules into host cells. Typically, transformed hosts are selected for their ability to grow on selective media. Selective media may incorporate an antibiotic or lack a factor necessary for growth of the untransformed host, such as a nutrient or growth factor. An introduced marker gene therefor may confer antibiotic resistance, or encode an essential growth factor or enzyme, and permit growth on selective media when expressed in the transformed host cell. Desirably, resistance to kanamycin and the amino glycoside G418 are of interest (see U.S. Pat. No. 5,034,322). Selection of a transformed host can also occur when the expressed marker protein can be detected, either directly or indirectly. The marker protein may be expressed alone or as a fusion to another protein. The marker protein can be detected by its enzymatic activity; for example β galactosidase can convert the substrate X-gal to a colored product, and luciferase can convert luciferin to a light-emitting product. The marker protein can be detected by its light-producing or modifying characteristics; for example, the green fluorescent protein of Aequorea victoria fluoresces when illuminated with blue light. Antibodies can be used to detect the marker protein or a molecular tag on, for example, a protein of interest. Cells expressing the marker protein or tag can be selected, for example, visually, or by techniques such as FACS or panning using antibodies.

The PUFAs produced using the subject methods and compositions may be found in the host plant tissue and/or plant part as free fatty acids or in conjugated forms such as acylglycerols, phospholipids, sulfolipids or glycolipids, and may be extracted from the host cell through a variety of means well-known in the art. Such means may include extraction with organic solvents, sonication, supercritical fluid extraction using for example carbon dioxide, and physical means such as presses, or combinations thereof. Of particular interest is extraction with methanol and chloroform. Where desirable, the aqueous layer can be acidified to protonate negatively charged moieties and thereby increase partitioning of desired products into the organic layer. After extraction, the organic solvents can be removed by evaporation under a stream of nitrogen. When isolated in conjugated forms, the products are enzymatically or chemically cleaved to release the free fatty acid or a less complex conjugate of interest, and are then subjected to further manipulations to produce a desired end product. Desirably, conjugated forms of fatty acids are cleaved with potassium hydroxide.

If further purification is necessary, standard methods can be employed. Such methods include extraction, treatment with urea, fractional crystallization, HPLC, fractional distillation, silica gel chromatography, high speed centrifugation or distillation, or combinations of these techniques. Protection of reactive groups, such as the acid or alkenyl groups, may be done at any step through known techniques, for example alkylation or iodination. Methods used include methylation of the fatty acids to produce methyl esters. Similarly, protecting groups may be removed at any step. Desirably, purification of fractions containing ARA, DHA and EPA is accomplished by treatment with urea and/or fractional distillation.

The uses of the subject invention are several. Probes based on the DNAs of the present invention may find use in methods for isolating related molecules or in methods to detect organisms expressing desaturases. When used as probes, the DNAs or oligonucleotides need to be detectable. This is usually accomplished by attaching a label either at an internal site, for example via incorporation of a modified residue, or at the 5' or 3' terminus. Such labels can be directly detectable, can bind to a secondary molecule that is detectably labeled, or can bind to an unlabelled secondary molecule and a detectably labeled tertiary molecule; this process can be extended as long as is practical to achieve a satisfactorily detectable signal without unacceptable levels of background signal. Secondary, tertiary, or bridging systems can include use of antibodies directed against any other molecule, including labels or other antibodies, or can involve any molecules which bind to each other, for example a biotin-streptavidin/avidin system. Detectable labels typically include radioactive isotopes, molecules which chemically or enzymatically produce or alter light, enzymes which produce detectable reaction products, magnetic molecules, fluorescent molecules or molecules whose fluorescence or light-emitting characteristics change upon binding. Examples of labelling methods can be found in U.S. Pat. No. 5,011,770. Alternatively, the binding of target molecules can be directly detected by measuring the change in heat of solution on binding of probe to target via isothermal titration calorimetry, or by coating the probe or target on a surface and detecting the change in scattering of light from the surface produced by binding of target or probe, respectively, as may be done with the BIAcore system.

PUFAs produced by recombinant means find applications in a wide variety of areas. Supplementation of humans or animals with PUFAs in various forms can result in increased levels not only of the added PUFAs, but of their metabolic progeny as well. For example, where the inherent Δ6-desaturase pathway is dysfunctional in an individual, treatment with GLA can result not only in increased levels of GLA, but also of downstream products such as ARA and prostaglandins (see FIG. 1). Complex regulatory mechanisms can make it desirable to combine various PUFAs, or to add different conjugates of PUFAs, in order to prevent, control or overcome such mechanisms to achieve the desired levels of specific PUFAs in an individual.

PUFAs, or derivatives thereof, made by the disclosed method can be used as dietary supplements, particularly in infant formulas, for patients undergoing intravenous feeding or for preventing or treating malnutrition. Particular fatty acids such as EPA are used to alter the composition of infant formulas to better replicate the PUFA composition of human breast milk. The predominant triglyceride in human milk has been reported to be 1,3-di-oleoyl-2-palmitoyl, with 2-palmitoyl glycerides reported as better absorbed than 2-oleoyl or 2-lineoyl glycerides (U.S. Pat. No. 4,876,107). Typically, human breast milk has a fatty acid profile comprising from about 0.15% to about 0.36% as DHA, from about 0.03% to about 0.13% as EPA, from about 0.30% to about 0.88% as ARA, from about 0.22% to about 0.67% as DGLA, and from about 0.27% to about 1.04% as GLA. A preferred ratio of GLA:DGLA:ARA in infant formulas is from about 1:1:4 to about 1:1:1, respectively. Amounts of oils providing these ratios of PUFA can be determined without undue experimentation by one of skill in the art. PUFAs, or host cells containing them, also can be used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption.

For dietary supplementation, the purified PUFAs, or derivatives thereof, may be incorporated into cooking oils, fats or margarines formulated so that in normal use the recipient would receive the desired amount. The PUFAs may also be incorporated into infant formulas, nutritional supplements or other food products, and may find use as anti-inflammatory or cholesterol lowering agents.

For pharmaceutical use (human or veterinary), the compositions are generally administered orally but can be administered by any route by which they may be successfully absorbed, e.g., parenterally (i.e. subcutaneously, intramuscularly or intravenously), rectally or vaginally or topically, for example, as a skin ointment or lotion. Where available, gelatin capsules are the preferred form of oral administration. Dietary supplementation as set forth above can also provide an oral route of administration. The unsaturated acids of the present invention may be administered in conjugated forms, or as salts, esters, amides or prodrugs of the fatty acids. Any pharmaceutically acceptable salt is encompassed by the present invention; especially preferred are the sodium, potassium or lithium salts. Also encompassed are the N-alkylpolyhydroxamine salts, such as N-methyl glucamine, described in PCT publication WO 96/33155. Preferred esters are the ethyl esters.

The PUFAs of the present invention may be administered alone or in combination with a pharmaceutically acceptable carrier or excipient. As solid salts, the PUFAs can also be administered in tablet form. For intravenous administration, the PUFAs or derivatives thereof may be incorporated into commercial formulations such as Intralipids. Where desired, the individual components of formulations may be individually provided in kit form, for single or multiple use. A typical dosage of a particular fatty acid is from 0.1 mg to 20 g, or even 100 g daily, and is preferably from 10 mg to 1, 2, 5 or 10 g daily as required, or molar equivalent amounts of derivative forms thereof. Parenteral nutrition compositions comprising from about 2 to about 30 weight percent fatty acids calculated as triglycerides are encompassed by the present invention; especially preferred is a composition having from about 1 to about 25 weight percent of the total fatty acid composition as GLA (U.S. Pat. No. 5,196,198). Other vitamins, and particularly fat-soluble vitamins such as vitamin A, D, E and L-carnitine can optionally be included. Where desired, a preservative such as α tocopherol may be added, typically at about 0.1% by weight. The typical normal adult plasma fatty acid profile comprises 6.64 to 9.46% of ARA, 1.45 to 3.11% of DGLA, and 0.02 to 0.08% of GLA. These PUFAs or their metabolic precursors can be administered, either alone or in mixtures with other PUFAs, to achieve a normal fatty acid profile in a patient.

The following examples are presented by way of illustration, not of limitation.

EXAMPLES

Example 1 Isolation of Δ5 Desaturase Nucleotide Sequence from Mortierella alpina

Example 2 Isolation of Δ6 Desaturase Nucleotide Sequence from Mortierella alpina

Example 3 Identification of Δ6 Desaturases Homologues to the Mortierella alpina Δ6 Desaturase

Example 4 Isolation of Δ12 Desaturase Nucleotide Sequence from Mortierella alpina

Example 5 Isolation of Cytochrome b5 Reductase Nucleotide Sequence from Mortierella alpina

Example 6 Expression of M. alpina Desaturase Clones in Baker's Yeast

Example 7 Fatty Acid Analysis of Leaves from Ma29 Transgenic Brassica Plants

Example 8 Expression of M. alpina Δ6 Desaturase in Brassica napus

Example 1 Isolation of a Δ5-desaturase Nucleotide Sequence from Mortierella Alpina

Motierella alpina produces arachidonic acid (ARA, 20:4) from the precursor 20:3 by a Δ5-desaturase. A nucleotide sequence encoding the Δ5-desaturase from Mortierella alpina was obtained through PCR amplification using M. alpina 1^(st) strand cDNA and degenerate oligonucleotide primers corresponding to amino acid sequences conserved between Δ6-desaturases from Synechocystis and Spirulina. The procedure used was as follows:

Total RNA was isolated from a 3 day old PUFA-producing culture of Mortierella alpina using the protocol of Hoge et al. (1982) Experimental Mycology 6:225-232. The RNA was used to prepare double-stranded cDNA using BRL's lambda-ZipLox system, following the manufacturer's instructions. Several size fractions of the M. alpina cDNA were packaged separately to yield libraries with different average-sized inserts. The "full-length" library contains approximately 3×10⁶ clones with an average insert size of 1.77 kb. The "sequencing-grade" library contains approximately 6×10⁵ clones with an average insert size of 1.1 kb.

5 μg of total RNA was reverse transcribed using BRL Superscript RTase and the primer TSyn (5'-CCAAGCTTCTGCAGGAGCTCTTTTTTTTTTTTTTT-3') (SEQ ID NO:18). Degenerate oligonucleotides were designed to regions conserved between the two cyanobacterial Δ6-desaturase sequences. The specific primers used were D6DESAT-F3 (5'-CUACUACUACUACAYCAYACOTAYACOAAYAT-3') (SEQ ID NO:19) and D6DESAT-R3 (5'-CAUCAUCAUCAUOGGRAAOARRTGRTG-3') (SEQ ID NO:20), where Y=C+T, R=A+G, and O=I+C. PCR amplification was carried out in a 25 μl volume containing: template derived from 40 ng total RNA, 2 pM each primer, 200 μM each deoxyribonucleotide triphosphate, 60 mM Tris-Cl, pH 8.5, 15 mM (NH₄)₂ SO₄, 2 mM MgCl₂. Samples were subjected to an initial desaturation step of 95 degrees (all temperatures Celsius) for 5 minutes, then held at 72 degrees while 0.2 U of Taq polymerase were added. PCR thermocycling conditions were as follows: 94 degrees for 1 min., 45 degrees for 1.5 min., 72 degrees for 2 min. PCR was continued for 35 cycles. PCR using these primers on the M. alpina first-strand cDNA produced a 550 bp reaction product. Comparison of the deduced amino acid sequence of the M. alpina PCR fragment (SEQ ID NO:13, FIG. 6) revealed regions of homology with Δ6-desaturases. However, there was only about 28% identity over the region compared.

The PCR product was used as a probe to isolate corresponding cDNA clones from a M. alpina library. The longest cDNA clone, Ma29, was designated pCGN5521 and has been completely sequenced on both strands. The cDNA is contained as a 1481 bp insert in the vector pZL1 (Bethesda Research Laboratories) and, beginning with the first ATG, contains an open reading frame encoding 446 amino acids (SEQ ID NO:5). The reading frame contains the sequence deduced from the PCR fragment. The deduced amino acid sequence of the cDNA insert was found to contain regions of homology to Δ6-desaturases (see FIG. 7). For example, three conserved "histidine boxes" (that have been observed in all other membrane-bound desaturases (Okuley et al., (1994) The Plant Cell 6:147-158)) were found to be present in the Mortierella sequence at amino acid positions 171-175, 207-212, and 387-391 (see FIG. 7). However, the typical "HXXHH" amino acid motif for the third histidine box for the Mortierella desaturase was found to be QXXHH. Surprisingly, the amino-terminus of the encoded protein, showed significant homology to cytochrome b5 proteins. Thus, the Mortierella cDNA clone appears to represent a fusion between a cytochrome b5 and a fatty acid desaturase. Since cytochrome b5 is believed to function as the electron donor for membrane-bound desaturase enzymes, it is possible that the N-terminal cytochrome b5 domain of this desaturase protein is involved in its function. This may be advantageous when expressing the desaturase in heterologous systems for PUFA production.

Example 2 Isolation of Δ6 Desaturase Nucleotide Sequence from Mortierella alpina

A nucleic acid sequence from a partial cDNA clone, Ma524, encoding a Δ6 fatty acid desaturase from Mortierella alpina was obtained by random sequencing of clones from the M. alpina cDNA library described in Example 1. cDNA-containing plasmids were excised as follows:

Five μl of phage were combined with 100 μl of E. coli DH10B(ZIP) grown in ECLB plus 10 μg/ml kanamycin, 0.2% maltose, and 10 mM MgSO₄ and incubated at 37 degrees for 15 minutes. 0.9 ml SOC was added and 100 μl of the bacteria immediately plated on each of 10 ECLB+50 μg Pen plates. No 45 minute recovery time was needed. The plates were incubated overnight at 37 degrees. Colonies were picked into ECLB+50 μg Pen media for overnight cultures to be used for making glycerol stocks and miniprep DNA. An aliquot of the culture used for the miniprep is stored as a glycerol stock. Plating on ECLB+50 μg Pen/ml resulted in more colonies and a greater proportion of colonies containing inserts than plating on 100 μg/ml Pen.

Random colonies were picked and plasmid DNA purified using Qiagen miniprep kits. DNA sequence was obtained from the 5' end of the cDNA insert and compared to the databases using the BLAST algorithm. Ma524 was identified as a putative Δ6 desaturase based on DNA sequence homology to previously identified Δ6 desaturases. A full-length cDNA clone (SEQ ID NO:1) was isolated from the M. alpina library and the amino acid sequence (FL) (SEQ ID NO:2) was deduced. The abundance of this clone appears to be slightly (2×) less than Ma29. Ma524 deduced amino acid sequence (SEQ ID NO:6) displays significant homology to a portion of a Caenorhabditis elegans cosmid, WO6D2.4, a cytochrome b5/desaturase fusion protein from sunflower, and the two Δ6 desaturases in the public databanks those from Synechocystis and Spirulina.

In addition, Ma524 shows significant homology to the borage Δ6-desaturase sequence (PCT publication WO 96/21022). Ma524 thus appears to encode a Δ6-desaturase that is related to the borage and algal Δ6-desaturases. It should be noted that, although the amino acid sequences of Ma524 and the borage Δ6 are similar, the base composition of the cDNAs is quite different: the borage cDNA has an overall base composition of 60% A+T, with some regions exceeding 70%, while Ma524 has an average of 44% A+T base composition, with no regions exceeding 60%. This may have implications for expressing the cDNAs in microorganisms or animals which favor different base compositions. It is known that poor expression of recombinant genes can occur when the host has a very different base composition from that of the introduced gene. Speculated mechanisms for such poor expression include decreased stability or translatability of the MRNA.

Example 3 Identification of Δ6-desaturases Homologous to the Mortierella Alpina Δ6-desaturase

Nucleic acid sequences that encode putative Δ6-desaturases were identified through a BLASTX search of the est databases through NCBI using the Ma524 amino acid sequence. Several sequences showed significant homology. In particular, the deduced amino acid sequence of two Arabidopsis thaliana sequences, (accession numbers F13728 and T42806) showed homology to two different regions of the deduced amino acid sequence of Ma524. The following PCR primers were designed: ATTS4723-FOR (complementary to F13728) 5'-CUACUACUACUAGGAGTCCTCTACGGTGTTTTG (SEQ ID NO:21) and T42806-REV (complementary to T42806) 5' UCAUCAUCAUATGATGCTCAAGCTGAAACTG (SEQ ID NO:22). Five μg of total RNA isolated from developing siliques of Arabidopsis thaliana was reverse transcribed using BRL Superscript RTase and the primer TSyn (5'-CCAAGCTTCTGCAGGAGCTCTTTTTTTTTTTTTTT-3'). PCR was carried out in a 50 μl volume containing: template derived from 25 ng total RNA, 2 pM each primer, 200 μM each deoxyribonucleotide triphosphate, 60 mM Tris-Cl, pH 8.5, 15 mM (NH₄)₂ SO₄, 2 mM MgCl₂, 0.2 U Taq Polymerase. Cycle conditions were as follows: 94 degrees for 30 sec., 50 degrees for 30 sec., 72 degrees for 30 sec. PCR was continued for 35 cycles followed by an additional extension at 72 degrees for 7 minutes. PCR resulted in a fragment of ˜750 base pairs which was subsequently subcloned, named 12-5, and sequenced. Each end of this fragment corresponds to the Arabidopsis est from which the PCR primers were derived. This is the sequence named 12-5. The deduced amino acid sequence of 12-5 (SEQ ID NO:8) is compared to that of Ma524 and ests from human (W28140) (SEQ ID NO:10), mouse (W53753) (SEQ ID NO:12), and C. elegans (R05219) (SEQ ID NO:11) in FIG. 4. Based on homology, these sequences represent desaturase polypeptides. The full-length genes can be cloned using probes based on the est sequences. The genes can then be placed in expression vectors and expressed in host cells and their specific Δ6- or other desaturase activity can be determined as described below.

Example 4 Isolation of Δ12 Desaturase Nucleotide Sequence from Mortierella alpina

Based on the fatty acids it accumulates, Mortierella alpina has an ω6 type desaturase. The Ω6 desaturase is responsible for the production of linoleic acid (18:2) from oleic acid (18:1). Linoleic acid (18:2) is a substrate for a Δ6 desaturase. This experiment was designed to determine if Mortierella alpina has a Δ12-desaturase polypeptide, and if so, to identify the corresponding nucleotide sequence. A random colony from the M. alpina sequencing grade library, Ma648, was sequenced and identified as a putative desaturase based on DNA sequence homology to previously identified desaturases, as described for Ma524 (see Example 2). The deduced amino acid sequence from the 5' end of the Ma648 cDNA displays significant homology to soybean microsomal ω6 (Δ12) desaturase (accession #L43921) as well as castor bean oleate 12-hydroxylase (accession #U22378). In addition, homology is observed to a variety of other ω6 (Δ12) and ω3 (Δ15) fatty acid desaturase sequences.

Example 5 Isolation of Cytochrome b5 Reductase Nucleotide Sequence from Mortierella alpina

A nucleic acid sequence encoding a cytochrome b5 reductase from Mortierella alpina was obtained as follows. A cDNA library was constructed based on total RNA isolated from Mortierella alpina as described in Example 1. DNA sequence was obtained from the 5' and 3' ends of one of the clones, M12-27. A search of public databanks with the deduced amino acid sequence of the 3' end of M12-27 revealed significant homology to known cytochrome b5 reductase sequences. Specifically, over a 49 amino acid region, the Mortierella clone shares 55% identity (73% homology) with a cytochrome b5 reductase from pig.

Example 6 Expression of M. Alpina Desaturase Clones in Baker's Yeast

Yeast Transformation

Lithium acetate transformation of yeast was performed according to standard protocols (Methods in Enzymology, Vol. 194, p. 186-187, 1991). Briefly, yeast were grown in YPD at 30° C. Cells were spun down, resuspended in TE, spun down again, resuspended in TE containing 100 mM lithium acetate, spun down again, and resuspended in TE/lithium acetate. The resuspended yeast were incubated at 30° C. for 60 minutes with shaking. Carrier DNA was added, and the yeast were aliquoted into tubes. Transforming DNA was added, and the tubes were incubated for 30 min. at 30° C. PEG solution (35% (w/v) PEG 4000, 100 mM lithium acetate, TE pH7.5) was added followed by a 50 min. incubation at 30° C. A 5 min. heat shock at 42° C. was performed, the cells were pelleted, washed with TE, pelleted again and resuspended in TE. The resuspended cells were then plated on selective media.

Desaturase Expression in Transformed Yeast

cDNA clones from Mortierella alpina were screened for desaturase activity in baker's yeast. A canola Δ15-desaturase (obtained by PCR using 1^(st) strand cDNA from Brassica napus cultivar 212/86 seeds using primers based on the published sequence (Arondel et al. Science 258:1353-1355)) was used as a positive control. The Δ15-desaturase gene and the gene from cDNA clone Ma29 were individually put in the expression vector pYES2 (Invitrogen), resulting in plasmids pCGR-2 and pCGR-4, respectively. These plasmids were transfected into S. cerevisiae yeast strain 334 and expressed after induction with galactose and in the presence of substrates that allowed detection of specific desaturase activity. The control strain was S. cerevisiae strain 334 containing the unaltered pYES2 vector. The substrates used, the products produced and the indicated desaturase activity were: DGLA (conversion to ARA would indicate Δ5-desaturase activity), linoleic acid (conversion to GLA would indicate Δ6-desaturase activity; conversion to ALA would indicate Δ15-desaturase activity), oleic acid (an endogenous substrate made by S. cerevisiae, conversion to linoleic acid would indicate Δ12-desaturase activity, which S. cerevisiae lacks), or ARA (conversion to EPA would indicate Δ17-desaturase activity). The results are provided in Table 1 below. The lipid fractions were extracted as follows: Cultures were grown for 48-52 hours at 15° C. Cells were pelleted by centrifugation, washed once with sterile ddH₂ O, and repelleted. Pellets were vortexed with methanol; chloroform was added along with tritridecanoin (as an internal standard). The mixtures were incubated for at least one hour at room temperature or at 4° C. overnight. The chloroform layer was extracted and filtered through a Whatman filter with one gram of anhydrous sodium sulfate to remove particulates and residual water. The organic solvents were evaporated at 40° C. under a stream of nitrogen. The extracted lipids were then derivatized to fatty acid methyl esters (FAME) for gas chromatography analysis (GC) by adding 2 ml of 0.5 N potassium hydroxide in methanol to a closed tube. The samples were heated to 95° C. to 100° C. for 30 minutes and cooled to room temperature. Approximately 2 ml of 14% boron trifluoride in methanol was added and the heating repeated. After the extracted lipid mixture cooled, 2 ml of water and 1 ml of hexane were added to extract the FAME for analysis by GC. The percent conversion was calculated by dividing the product produced by the sum of (the product produced and the substrate added) and then multiplying by 100. To calculate the oleic acid percent conversion, as no substrate was added, the total linoleic acid produced was divided by the sum of (oleic acid and linoleic acid produced), then multiplied by 100.

                  TABLE 1                                                          ______________________________________                                         M. Alpina Desaturase Expression in Baker's Yeast                                               ENZYME    % CONVERSION                                           CLONE ACTIVITY OF SUBSTRATE                                                  ______________________________________                                         pCGR-2      Δ6  0        (18:2 to 18:3ω6)                            (canola Δ15 Δ15 16.3 (18:2 to 18:3ω3)                        desaturase) Δ5  2.0 (20:3 to 20:4ω6)                                Δ17 2.8 (20:4 to 20:5ω3)                                           Δ12 1.8 (18:1 to 18:2ω6)                                          pCGR-4 Δ6  0                                                             (M. alpina Δ15 0                                                         Ma29) Δ5  15.3                                                            Δ17 0.3                                                                  Δ12 3.3                                                                 pCGR-7 Δ6  0                                                             (M. alpina Δ15 3.8                                                       Ma648) Δ5  2.2                                                            Δ17 0                                                                    Δ12 63.4                                                              ______________________________________                                    

The Δ15-desaturase control clone exhibited 16.3% conversion of the substrate. The pCGR-4 clone expressing the Ma29 cDNA converted 15.3% of the 20:3 substrate to 20:4ω6, indicating that the gene encodes a Δ5-desaturase. The background (non-specific conversion of substrate) was between 0-3% in these cases. The pCGR-5 clone expressing the Ma524 cDNA showed 6% conversion of the substrate to GLA, indicating that the gene encodes a Δ6-desaturase. The pCGR-7 clone expressing the Ma648 cDNA converted 63.4% conversion of the substrate to LA, indicating that the gene encodes a Δ12-desaturase. Substrate inhibition of activity was observed by using different concentrations of the substrate. When substrate was added to 100 μM, the percent conversion to product dropped as compared to when substrate was added to 25 μM (see below). These data show that desaturases with different substrate specificities can be expressed in a heterologous system and used to produce PUFAs.

Table 2 represents fatty acids of interest as a percent of the total lipid extracted from the yeast host S. cerevisiae 334 with the indicated plasmid. No glucose was present in the growth media. Affinity gas chromatography was used to separate the respective lipids. GC/MS was employed to verify the identity of the product(s). The expected product for the B. napus Δ15-desaturase, α-linolenic acid, was detected when its substrate, linoleic acid, was added exogenously to the induced yeast culture. This finding demonstrates that yeast expression of a desaturase gene can produce functional enzyme and detectable amounts of product under the current growth conditions. Both exogenously added substrates were taken up by yeast, although slightly less of the longer chain PUFA, dihomo-γ-linolenic acid (20:3), was incorporated into yeast than linoleic acid (18:2) when either was added in free form to the induced yeast cultures. γ-linolenic acid was detected when linoleic acid was present during induction and expression of S. cerevisiae 334 (pCGR-5). The presence of this PUFA demonstrates Δ6-desaturase activity from pCGR-5 (MA524). Linoleic acid, identified in the extracted lipids from expression of S. cerevisiae 334 (pCGR-7), classifies the cDNA MA648 from M. alpina as the Δ12-desaturase.

                                      TABLE 2                                      __________________________________________________________________________     Fatty Acid as a Percentage of Total Lipid Extracted from Yeast                 Plasmid                                                                          in Yeast 18:2 α-18:3 γ-18:3 20:3 20:4 18:1* 18:2                   (enzyme) Incorporated Produced Produced Incorporated Produced Present                                            Produced                                   __________________________________________________________________________     pYES2                                                                               66.9  0    0    58.4  0    4   0                                            (control)                                                                      pCGR-2 60.1 5.7 0 50.4 0 0.7 0                                                 (Δ15)                                                                    pCGR-4 67 0 0 32.3 5.8 0.8 0                                                   (Δ5)                                                                     pCGR-5 62.4 0 4.0 49.9 0 2.4 0                                                 (Δ6)                                                                     pCGR-7 65.6 0 0 45.7 0 7.1 12.2                                                (Δ12)                                                                  __________________________________________________________________________      100 μM substrate added                                                      *18:1 is an endogenous fatty acid in yeast                                     Key To Tables                                                                  18:1 = oleic acid                                                              18:2 = linoleic acid                                                           18:3 = linolenic acid                                                          8:3 = linolenic acid                                                           18:4 = stearidonic acid                                                        20:3 = dihomolinolenic acid                                                    20:4 = arachidonic acid                                                  

Example 7 Expression of Δ5 Desaturase in Plants

Expression in Leaves

This experiment was designed to determine whether leaves expressing Ma29 (as determined by Northern) were able to convert exogenously applied DGLA (20:3) to ARA (20:4).

The Ma29 desaturase cDNA was modified by PCR to introduce convenient restriction sites for cloning. The desaturase coding region has been inserted into a d35 cassette under the control of the double 35S promoter for expression in Brassica leaves (pCGN5525) following standard protocols (see U.S. Pat. No. 5,424,200 and U.S. Pat. No. 5,106,739). Transgenic Brassica plants containing pCGN5525 were generated following standard protocols (see U.S. Pat. No. 5,188,958 and U.S. Pat. No. 5,463,174).

In the first experiment, three plants were used: a control, LPOO4-1, and two transgenics, 5525-23 and 5525-29. LP004 is a low-linolenic Brassica variety. Leaves of each were selected for one of three treatments: water, GLA or DGLA. GLA and DGLA were purchased as sodium salts from NuChek Prep and dissolved in water at 1 mg/ml. Aliquots were capped under N₂ and stored at -70 degrees C. Leaves were treated by applying a 50 μl drop to the upper surface and gently spreading with a gloved finger to cover the entire surface. Applications were made approximately 30 minutes before the end of the light cycle to minimize any photo-oxidation of the applied fatty acids. After 6 days of treatment one leaf from each treatment was harvested and cut in half through the mid rib. One half was washed with water to attempt to remove unincorporated fatty acid. Leaf samples were lyophilized overnight, and fatty acid composition determined by gas chromatography (GC). The results are shown in Table 3.

                                      TABLE 3                                      __________________________________________________________________________     Fatty Acid Analysis of Leaves from Ma29 Transgenic Brassica Plants             __________________________________________________________________________          SPL                                                                               16:00                                                                             16:01                                                                             18:00                                                                             18:01                                                                             18:1o                                                                             18:1v                                                                             18:02                                                                             18:3g                                                                             18:03                                                                             18:04                                                                             20:00                                                                             20:01                                                                             20:02                                                                             20:03                             Treatment # % % % % % % % % % % % % % %                                      __________________________________________________________________________       Water 33 12.95 0.08 2.63 2.51 1.54 0.98 16.76 0 45.52 0 0.09 0 0 0                                                            34 13.00 0.09 2.67 2.56                                                      1.55 1.00 16.86 0 44.59 0                                                      0.15 0 0.01 0                      35 14.13 0.09 2.37 2.15 1.27 0.87 16.71 0 49.91 0 0.05 0.01 0.01 0                                                           36 13.92 0.08 2.32 2.07                                                      1.21 0.86 16.16 0 50.25 0                                                      0.05 0 0 0.01                      37 13.79 0.11 2.10 2.12 1.26 0.86 15.90 0.08 46.29 0 0.54 0.01 0.02 0                                                        38 12.80 0.09 1.94 2.08                                                      1.35 0.73 14.54 0.11 45.61                                                     0 0.49 0.01 0.01 0                                                              GLA 39 12.10 0.09 2.37                                                        2.10 1.29 0.82 14.85 1.63                                                      43.66 0 0.53 0 0.02 0.01                                                         40 12.78 0.10 2.34 2.22                                                      1.36 0.86 15.29 1.72 47.22                                                     0 0.50 0.02 0.01 0                                                               41 13.71 0.07 2.68 2.16                                                      1.34 0.82 15.92 2.12 46.55                                                     0 0.09 0 0 0                       42 14.10 0.07 2.75 2.35 1.51 0.84 16.66 1.56 46.41 0 0.09 0.01 0 0                                                           43 13.62 0.09 2.22 1.94                                                      1.21 0.73 14.68 2.42 46.69                                                     0 0.51 0.01 0.01 0                                                               44 13.92 0.09 2.20 2.17                                                      1.32 0.85 15.22 2.30 46.05                                                     0 0.53 0.02 0.02 0                                                              DGLA 45 12.45 0.14 2.30                                                       2.28 1.37 0.91 15.65 0.07                                                      44.62 0 0.12 0.01 0.06                                                         1.21                               46 12.67 0.15 2.69 2.50 1.58 0.92 15.96 0.09 42.77 0 0.56 0.01 0 1.94                                                        47 12.56 0.23 3.40 1.98                                                      1.13 0.86 13.57 0.03 45.52                                                     0 0.51 0.01 0.01 0.69                                                            48 13.07 0.24 3.60 2.51                                                      1.63 0.88 13.54 0.04 45.13                                                     0 0.50 0.01 0.01 0.70                                                            49 13.26 0.07 2.81 2.34                                                      1.67 0.67 16.04 0.04 43.89                                                     0 0.59 0 0 0.35                    50 13.53 0.07 2.84 2.41 1.70 0.70 16.07 0.02 44.90 0 0.60 0.01 0            __________________________________________________________________________                                                    0.20                                                SPL                                                                               20:04                                                                             20:05                                                                             22:00                                                                             22:01                                                                             22:02                                                                             22:03                                                                             22:06                                                                             24:0                                                                              24:1                              Treatment # % % % % % % % % %                                                __________________________________________________________________________       Water 33 0.29 0 0.01 0.09 16.26 0 0 0.38 0.18                                   34 0.26 0 0.14 0.10 16.82 0.02 0.05 0.36 0.27                                  35 0.25 0 0.12 0.06 11.29 0.04 0.05 0.29 0.25                                  36 0.26 0 0.07 0.04 11.82 0.03 0.36 0.28 0.21                                  37 0.21 0 0.18 0.08 15.87 0.06 0.20 0.30 0.17                                  38 0.24 0 0.15 0.07 13.64 0.09 0.08 5.89 0.23                                 GLA 39 0.27 0 0.10 0.08 16.25 3.42 0.19 0.37 0.17                               40 0.27 0 0.10 0.10 14.74 0.05 0.10 0.36 0.14                                  41 0.27 0 0.20 0.10 13.15 0.13 0.29 0.33 0.20                                  42 0.28 0 0.11 0.11 12.60 0.02 0.24 0.38 0.13                                  43 0.28 0 0.10 0.03 14.73 0.01 0.24 0.34 0.14                                  44 0.26 0 0.13 0.07 14.43 0.05 0.16 0.33 0.17                                 DGLA 45 0.26 0 0.07 0.07 18.67 0.02 0.21 0.36 0.13                              46 0.27 0 0.11 0.09 17.97 0.09 0.39 0.41 0.11                                  47 0.96 0 0.11 0.07 17.96 0 0.22 0.49 0.20                                     48 0.74 0 0.14 0.09 17.14 0.05 0.32 0.52 0.10                                  49 1.11 0 0.10 0.07 17.26 0.07 0.23 0.39 0.18                                  50 0.87 0 0.21 0.07 15.73 0.04 0.15 0.37 0.18                               __________________________________________________________________________

Leaves treated with GLA contained from 1.56 to 2.4 wt % GLA. The fatty acid analysis showed that the lipid composition of control and transgenic leaves was essentially the same. Leaves of control plants treated with DGLA contained 1.2-1.9 w % DGLA and background amounts of ARA (0.26-0.27 wt %). Transgenic leaves contained only 0.2-0.7 wt % DGLA, but levels of ARA were increased (0.74-1.1 wt %) indicating that the DGLA was converted to ARA in these leaves.

Expression in Seed

The purpose of this experiment was to determine whether a construct with the seed specific napin promoter would enable expression in seed.

The Ma29 cDNA was modified by PCR to introduce XhoI cloning sites upstream and downstream of the start and stop codons, respectively, using the following primers: Madxho-forward:

    5'-CUACUACUACUACTCGAGCAAGATGGGAACGGACCAAGG (SEQ ID NO:23)

Madxho-reverse:

    5'-CAUCAUCAUCAUCTCGAGCTACTCTTCCTTGGGACGGAG (SEQ ID NO:24).

The PCR product was subcloned into pAMP1 (GIBCOBRL) using the CloneAmp system (GIBCOBRL) to create pCGN5522 and the Δ5 desaturase sequence was verified by sequencing of both strands.

For seed-specific expression, the Ma29 coding region was cut out of pCGN5522 as an XhoI fragment and inserted into the SalI site of the napin expression cassette, pCGN3223, to create pCGN5528. The HindIII fragment of pCGN5528 containing the napin 5' regulatory region, the Ma29 coding region, and the napin 3' regulatory region was inserted into the HindIII site of pCGN1557 to create pCGN5531. pCGN5531 was introduced into Brassica napus cv.LP004 via Agrobacterium mediated transformation.

The fatty acid composition of twenty-seed pools of mature T2 seeds was analyzed by GC. Table 4 shows the results obtained with independent transformed lines as compared to non-transformed LP004 seed. The transgenic seeds containing pCGN5531 contain two fatty acids that are not present in the control seeds, tentatively identified as taxoleic acid (5,9-18:2) and pinolenic acid (5,9,12-18:3), based on their elution relative to oleic and linoleic acid. These would be the expected products of Δ5 desaturation of oleic and linoleic acids. No other differences in fatty acid composition were observed in the transgenic seeds.

                                      TABLE 4                                      __________________________________________________________________________     Composition of T2 Pooled Seed                                                         16:0                                                                              16:1                                                                              18:0                                                                              18:1                                                                              (5,9)18:2                                                                           18:2                                                                              (5,9,12)18:3                                                                         18:3                                                                              20:0                                                                              20:1                                                                              20:2                                                                              22:0                                                                              22:1                                                                              24:0                          % % % % % % % % % % % % % %                                                  __________________________________________________________________________     LP004 control                                                                         3.86                                                                              0.15                                                                              3.05                                                                              69.1                                                                              0    18.51                                                                             0.01  1.65                                                                              1.09                                                                              1.40                                                                              0.03                                                                              0.63                                                                              0.05                                                                              0.42                          5531-1 4.26 0.15 3.23 62.33 4.07 21.44 0.33 1.38 0.91 1.04 0.05 0.41                                                            0.03 0.27                     5531-2 3.78 0.14 3.37 66.18 4.57 17.31 0.27 1.30 1.03 1.18 0 0.47 0.01                                                          0.30                          5531-6 3.78 0.13 3.47 63.61 6.21 17.97 0.38 1.34 1.04 1.14 0.05 0.49                                                            0.02 0.26                     5531-10 3.96 0.17 3.28 63.82 5.41 18.58 0.32 1.43 0.98 1.11 0.02 0.50 0                                                         0.13                          5531-16 3.91 0.17 3.33 64.31 5.03 18.98 0.33 1.39 0.96 1.11 0 0.44 0 0                                                           5531-28 3.81 0.13                                                             2.58 62.64 5.36 20.95                                                          0.45 1.39 0.83 1.15                                                            0.01 0.36 0.05              __________________________________________________________________________                                                        0.21                   

The purpose of this experiment is to determine whether a tandem binary construct containing two copies of the Ma29 desaturase with the seed specific napin promoter would provide for higher expression per genetic locus. A binary construct is prepared and transformed into LPOO4 Brassica plants as described above in Example 7.

Northern analysis is performed on plants to identify those expressing Ma29. Developing embryos are isolated approximately 25 days post anthesis or when the napin promoter is induced, and floated in a solution containing GLA or DGLA as described in Example 7. Fatty acid analysis of the embryos is then performed by GC to determine the amount of conversion of DGLA to ARA, following the protocol adapted for leaves in Example 7. The amount of ARA incorporated into triglycerides by endogenous Brassica acyltransferasees is then evaluated by GC analysis as in Example 7.

Example 8 Expression of M. alpina Δ6 Desaturase in Brassica napus

The Ma524 cDNA was modified by PCR to introduce cloning sites using the following primers:

Ma524PCR-1

    5'-CUACUACUACUATCTAGACTCGAGACCATGGCTGCTGCTCCAGTGTG (SEQ ID NO:25)

Ma524PCR-2

    5'-CAUCAUCAUCAUAGGCCTCGAGTTACTGCGCCTTACCCAT

These primers allowed the amplification of the entire coding region and added XbaI and XhoI sites to the 5'-end and XhoI and StuI sites to the 3' end. The PCR product was subcloned into pAMP1 (GIBCOBRL) using the CloneAmp system (GIBCOBRL) to create pCGN5535 and the Δ6 desaturase sequence was verified by sequencing of both strands.

For seed-specific expression, the Ma524 coding region was cut out of pCGN5535 as an XhoI fragment and inserted into the SalI site of the napin expression cassette, pCGN3223, to create pCGN5536. The NotI fragment of pCGN5536 containing the napin 5' regulatory region, the Ma524 coding region, and the napin 3' regulatory region was inserted into the NotI site of pCGN1557 to create pCGN5538. pCGN5538 was introduced into Brassica napus cv.LP004 via Agrobacterium mediated transformation.

Maturing T2 seeds were collected from 6 independent transformation events in the greenhouse. The fatty acid composition of single seeds was analyzed by GC. Table 4 shows the results of control LP004 seeds and six 5538 lines. All of the 5538 lines except #8 produced seeds containing GLA. Presence of GLA segregated in these seeds as is expected for the T2 selfed seed population. In addition to GLA, the M. aplina Δ6 desaturase is capable of producing 18:4 (stearidonic) and another fatty acid believed to be the 6,9-18:2.

The above results show that desaturases with three different substrate specificities can be expressed in a heterologous system and used to produce poly-unsaturated long chain fatty acids. Exemplified were the production of ARA (20:4) from the precursor 20:3 (DGLA), the production of GLA (18:3) from 18:2 substrate, and the conversion of 18:1 substrate to 18:2, which is the precursor for GLA.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

                                      TABLE 5                                      __________________________________________________________________________     Fatty Acid Analysis of Seeds from Ma524 Transgenic Brassica Plants             SPL  16:0                                                                              16:1                                                                              18:0  6,9 18:2                                                                           18:2                                                                              18:3ga                                                                             18:3                                                                              18:4                                                                              20:1                                                                              22:0                                                                              22:1                                                                              24:0                                                                              24:1                               #  % % % 18:1 % % % % % % % % % %                                            __________________________________________________________________________     LP004-1                                                                             4.33                                                                              0.21                                                                              3.78                                                                              72.49                                                                             0   13.97                                                                             0   1.7                                                                               0  1.34                                                                              0.71                                                                              0.02                                                                              0.58                                                                              0.27                              2 4.01 0.16 3.09 73.59 0 14.38 0.01 1.4 0 1.43 0.66 0.02 0.6 0.2               3 4.12 0.19 3.66 70.25 0 17.28 0 1.57 0 1.28 0.5 0.02 0.39 0.2                 4 4.22 0.2 2.7 70.25 0 17.56 0 1.81 0 1.31 0.53 0.02 0.4 0.24                  5 4.02 0.18 3.41 72.91 0 14.45 0.01 1.45 0 1.37 0.7 0.02 0.51 0.26             6 4.22 0.18 3.23 71.47 0 15.92 0.01 1.52 0 1.32 0.69 0.02 0.51 0.27            7 4.1 0.16 3.47 72.08 0 15.23 0 1.52 0 1.32 0.63 0.03 0.49 0.23                9 4.01 0.17 3.71 72.98 0 13.97 0.01 1.41 0 1.45 0.74 0.03 0.58 0.23            10 4.04 0.18 3.57 70.03 0 17.46 0 1.5 0 1.33 0.81 0.08 0.38 0.24                                                             5530-1-1 4.61 0.2 3.48                                                        68.12 1.37 10.68 7.48 1.04                                                     0.53 1.19 0.49 0.02 0.33                                                       0.13                              2 4.61 0.22 3.45 68.84 1.38 10.28 7.04 1.01 0.31 1.15 0.48 0.02 0.39 0         3 4.78 0.24 3.24 65.86 0 21.35 0 1.49 0 1.08 0.48 0.02 0.38 0.22               4 4.84 0.3 3.89 87.84 1.87 9.9 8.97 1.02 0.28 1.14 0.53 0.02 0.5 0.18          5 4.84 0.2 3.58 54.5 3.81 8.85 10.14 0.95 0.48 1.19 0.47 0.01 0.33 0.12        6 4.91 0.27 3.44 66.51 1.48 11.14 7.74 1.15 0.33 1.08 0.49 0.02 0.34                                                        0.13                              7 4.87 0.22 3.84 65.78 1.27 11.98 8.88 1.2 0 1.12 0.47 0.02 0.37 0.16          8 4.59 0.22 3.4 70.77 0 16.71 0 1.36 0 1.14 0.48 0.02 0.39 0.15                9 4.63 0.23 3.51 60.66 2.01 6.77 7.24 0.97 0 1.18 0.52 0.02 0.3 0.11           10 4.56 0.19 3.56 70.88 0 16.89 0 1.37 0 1.22 0.54 0.02 0.22 0.03                                                            5536-3-1 4.74 0.21 3.43                                                       87.82 1.29 10.91 7.77 1.03                                                     0.28 1.11 0.5 0.02 0.36                                                        0.14                              2 4.72 0.21 3.24 87.42 1.63 10.37 8.4 0.09 0 1.12 0.49 0.02 0.38 0.15          3 4.24 0.21 3.52 71.31 0 10.63 0 1.33 0 1.12 0.46 0.02 0.4 0.14                4 4.64 0.21 3.45 87.92 1.86 9.91 7.97 0.91 0.33 1.14 0.47 0.02 0.37 0.14       5 4.91 0.25 3.31 67.19 0 19.92 0.01 1.39 0 1.05 0.48 0.02 0.37 0.14            6 4.67 0.21 3.25 67.07 1.23 11.32 8.35 0.99 0 1.16 0.47 0.02 0.33 0.18         7 4.83 0.10 2.94 64.8 4.94 8.45 9.95 0.03 0.44 1.13 0.37 0.01 0.27 0.12        8 4.66 0.22 3.68 67.33 0.71 1.2 6.99 1.1 0.24 1.10 0.48 0.03 0.36 0.17         9 4.65 0.24 3.11 67.42 0.84 18.71 6.93 1.16 0.25 1.08 0.45 0.02 0.52                                                        0.17                              10 4.8 0.27 3.33 85.76 0.86 12.89 7.7 1.1 0.24 1.08 0.46 0.01 0.34 0.16                                                      5538-4-1 4.85 0.24 3.8                                                        62.41 0 24.88 0 1.6 0.01                                                       0.09 0.45 0.02 0.53 0.13          2 5.37 0.31 3 67.98 0.38 18.04 10.5 1.41 0 0.99 0.48 0.02 0.3 0.19             3 4.61 0.22 3.07 63.62 0.8 16.46 7.57 1.2 0 1.18 0.45 0.02 0.29 0.14           4 4.39 0.19 2.93 55.97 0 22.36 0 1.45 0 1.17 0.41 0.03 0.32 0.15               5 5.22 0.29 3.85 62.1 2.35 10.25 11.39 0.93 0.41 1.04 0.8 0.02 0.47 0.17       6 4.88 0.18 2.85 86.79 0.5 13.03 7.66 0.97 0.22 1.28 0.42 0.02 0.31 0.14       7 4.85 0.25 0.03 57.43 0.26 28.04 0.01 2.59 0.01 1.13 0.56 0.02 0.4 0.23       8 5.42 0.28 2.94 54.8 1.84 13.79 15.67 1.38 0.53 1.1 0.55 0.02 0.35 0.19       9 4.88 0.24 3.32 62.5 0.56 14.86 9.04 1.34 8.29 1.13 0.52 0.02 0.37 0.19       10 4.63 0.2 2.73 64.2 0.07 24.15 0 1.52 0 1.09 0.39 0.02 0.27 0.17                                                           5538-5-1 4.5 0.15 3.36                                                        66.71 0.88 11.7 8.38 1.04                                                      0.3 1.24 0.49 0.02 0.29                                                        0.17                              2 4.77 0.23 3.08 62.67 0.88 15.2 8.8 1.41 0.21 1.15 0.48 0.02 0.3 0.19         3 4.59 0.22 3.61 64.35 2.29 9.95 10.57 1.01 0.45 1.21 0.45 0.02 0.26                                                        0.16                              4 4.86 0.26 3.4 87.89 0.68 12.24 8.81 1.09 0.23 1.07 0.45 0.02 0.32 0.14       5 4.49 0.21 3.3 69.25 0.04 16.51 2.18 1.2 0 1.11 0.44 0.02 0.33 0.16           6 4.5 0.21 3.47 70.49 0.08 14.9 2.19 1.22 0 1.13 0.49 0.02 0.33 0.16           7 4.39 0.21 3.44 67.59 2.38 9.24 8.98 0.89 0 1.18 0.44 0.02 0.28 0.14          8 4.52 0.22 3.17 68.39 0.01 18.91 0.73 1.32 0.01 1.08 0.45 0.02 0.29                                                        0.17                              9 4.58 0.2 3.05 84.03 1.93 11.03 11.41 1.02 0.01 1.15 0.39 0.02 0.21                                                        0.15                              10 4.57 0.2 3.1 67.21 0.61 12.62 7.68 1.07 0.26 1.14 0.43 0.02 0.25 0.15        5538-8-1 4.95 0.28 3.14 84.04 0 23.38 0 1.64 0 0.99 0.42 0.02 0.38 0.17       2 4.91 0.26 3.71 62.33 0 23.97 0 1.77 0 0.95 0.53 0.02 0.42 0.19               3 4.73 0.26 4.04 62.83 0 22.36 0.01 1.73 0 1.05 0.55 0.02 0.45 0.16            4 5.1 0.35 3.8 60.45 0 24.45 0.01 2.13 0 1.07 0.65 0.03 0.63 0.24              5 4.96 0.3 3.91 82.48 0 23.44 0 1.77 0 1.01 0.51 0.01 0.43 0.21                6 4.62 0.21 3.99 66.14 0 20.38 0 1.48 0 1.15 0.53 0.02 0.48 0.19               7 4.84 0.22 3.55 64.6 0 22.85 0 1.38 0 1.09 0.45 0.02 0.41 0.19                8 5.65 0.38 3.16 56.5 0 30.83 0.02 0.02 0 0.98 0.56 0.03 0.39 0.26             9 8.53 0.63 6.9 51.76 0 28.01 0 0.01 0 1.41 1.21 0.07 0.96 0.33                10 5.52 0.4 3.97 57.92 0 28.95 0 0.02 0 0.95 0.52 0.02 0.41 0.16                                                             5538-10-1 4.44 0.19 3.5                                                       68.42 0 19.51 0 1.32 0 1.14                                                    0.45 0.02 0.31 0.16               2 4.57 0.21 3.07 88.08 0 21.98 0.01 1.36 0 1.12 0.41 0.02 0.31 0.16            3 4.63 0.21 3.48 67.43 0 20.27 0.01 1.32 0 1.12 0.48 0.02 0.21 0.08            4 4.59 0.19 3.22 64.62 0 23.16 0 1.35 0 1.08 0.46 0.02 0.38 0.2                5 4.58 0.2 3.4 68.75 0 20.17 0.01 0.02 0 1.1 0.45 0.02 0.34 0.17               8 4.55 0.21 0 73.55 0.05 14.91 2.76 1.21 0.07 1.24 0.51 0.02 0.19 0            9 4.58 0.21 3.28 68.19 0 21.55 0 1.35 0 1.12 0.43 0.02 0.33 0.18               10 4.52 0.2 3.4 68.37 0 19.33 0.01 1.3 0 1.13 0.46 0.02 0.35 0.18             __________________________________________________________________________

    __________________________________________________________________________     #             SEQUENCE LISTING                                                    - -  - - (1) GENERAL INFORMATION:                                              - -    (iii) NUMBER OF SEQUENCES: 26                                           - -  - - (2) INFORMATION FOR SEQ ID NO:1:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1617 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: DNA (genomic)                                      - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                - - CGACACTCCT TCCTTCTTCT CACCCGTCCT AGTCCCCTTC AACCCCCCTC TT -             #TGACAAAG     60                                                                  - - ACAACAAACC ATGGCTGCTG CTCCCAGTGT GAGGACGTTT ACTCGGGCCG AG -             #GTTTTGAA    120                                                                  - - TGCCGAGGCT CTGAATGAGG GCAAGAAGGA TGCCGAGGCA CCCTTCTTGA TG -             #ATCATCGA    180                                                                  - - CAACAAGGTG TACGATGTCC GCGAGTTCGT CCCTGATCAT CCCGGTGGAA GT -             #GTGATTCT    240                                                                  - - CACGCACGTT GGCAAGGACG GCACTGACGT CTTTGACACT TTTCACCCCG AG -             #GCTGCTTG    300                                                                  - - GGAGACTCTT GCCAACTTTT ACGTTGGTGA TATTGACGAG AGCGACCGCG AT -             #ATCAAGAA    360                                                                  - - TGATGACTTT GCGGCCGAGG TCCGCAAGCT GCGTACCTTG TTCCAGTCTC TT -             #GGTTACTA    420                                                                  - - CGATTCTTCC AAGGCATACT ACGCCTTCAA GGTCTCGTTC AACCTCTGCA TC -             #TGGGGTTT    480                                                                  - - GTCGACGGTC ATTGTGGCCA AGTGGGGCCA GACCTCGACC CTCGCCAACG TG -             #CTCTCGGC    540                                                                  - - TGCGCTTTTG GGTCTGTTCT GGCAGCAGTG CGGATGGTTG GCTCACGACT TT -             #TTGCATCA    600                                                                  - - CCAGGTCTTC CAGGACCGTT TCTGGGGTGA TCTTTTCGGC GCCTTCTTGG GA -             #GGTGTCTG    660                                                                  - - CCAGGGCTTC TCGTCCTCGT GGTGGAAGGA CAAGCACAAC ACTCACCACG CC -             #GCCCCCAA    720                                                                  - - CGTCCACGGC GAGGATCCCG ACATTGACAC CCACCCTCTG TTGACCTGGA GT -             #GAGCATGC    780                                                                  - - GTTGGAGATG TTCTCGGATG TCCCAGATGA GGAGCTGACC CGCATGTGGT CG -             #CGTTTCAT    840                                                                  - - GGTCCTGAAC CAGACCTGGT TTTACTTCCC CATTCTCTCG TTTGCCCGTC TC -             #TCCTGGTG    900                                                                  - - CCTCCAGTCC ATTCTCTTTG TGCTGCCTAA CGGTCAGGCC CACAAGCCCT CG -             #GGCGCGCG    960                                                                  - - TGTGCCCATC TCGTTGGTCG AGCAGCTGTC GCTTGCGATG CACTGGACCT GG -             #TACCTCGC   1020                                                                  - - CACCATGTTC CTGTTCATCA AGGATCCCGT CAACATGCTG GTGTACTTTT TG -             #GTGTCGCA   1080                                                                  - - GGCGGTGTGC GGAAACTTGT TGGCGATCGT GTTCTCGCTC AACCACAACG GT -             #ATGCCTGT   1140                                                                  - - GATCTCGAAG GAGGAGGCGG TCGATATGGA TTTCTTCACG AAGCAGATCA TC -             #ACGGGTCG   1200                                                                  - - TGATGTCCAC CCGGGTCTAT TTGCCAACTG GTTCACGGGT GGATTGAACT AT -             #CAGATCGA   1260                                                                  - - GCACCACTTG TTCCCTTCGA TGCCTCGCCA CAACTTTTCA AAGATCCAGC CT -             #GCTGTCGA   1320                                                                  - - GACCCTGTGC AAAAAGTACA ATGTCCGATA CCACACCACC GGTATGATCG AG -             #GGAACTGC   1380                                                                  - - AGAGGTCTTT AGCCGTCTGA ACGAGGTCTC CAAGGCTGCC TCCAAGATGG GT -             #AAGGCGCA   1440                                                                  - - GTAAAAAAAA AAACAAGGAC GTTTTTTTTC GCCAGTGCCT GTGCCTGTGC CT -             #GCTTCCCT   1500                                                                  - - TGTCAAGTCG AGCGTTTCTG GAAAGGATCG TTCAGTGCAG TATCATCATT CT -             #CCTTTTAC   1560                                                                  - - CCCCCGCTCA TATCTCATTC ATTTCTCTTA TTAAACAACT TGTTCCCCCC TT - #CACCG           1617                                                                        - -  - - (2) INFORMATION FOR SEQ ID NO:2:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 457 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                - - Met Ala Ala Ala Pro Ser Val Arg Thr Phe Th - #r Arg Ala Glu Val Leu       1               5   - #                10  - #                15                - - Asn Ala Glu Ala Leu Asn Glu Gly Lys Lys As - #p Ala Glu Ala Pro Phe                   20      - #            25      - #            30                    - - Leu Met Ile Ile Asp Asn Lys Val Tyr Asp Va - #l Arg Glu Phe Val Pro               35          - #        40          - #        45                        - - Asp His Pro Gly Gly Ser Val Ile Leu Thr Hi - #s Val Gly Lys Asp Gly           50              - #    55              - #    60                            - - Thr Asp Val Phe Asp Thr Phe His Pro Glu Al - #a Ala Trp Glu Thr Leu       65                  - #70                  - #75                  - #80         - - Ala Asn Phe Tyr Val Gly Asp Ile Asp Glu Se - #r Asp Arg Asp Ile Lys                       85  - #                90  - #                95                - - Asn Asp Asp Phe Ala Ala Glu Val Arg Lys Le - #u Arg Thr Leu Phe Gln                   100      - #           105      - #           110                   - - Ser Leu Gly Tyr Tyr Asp Ser Ser Lys Ala Ty - #r Tyr Ala Phe Lys Val               115          - #       120          - #       125                       - - Ser Phe Asn Leu Cys Ile Trp Gly Leu Ser Th - #r Val Ile Val Ala Lys           130              - #   135              - #   140                           - - Trp Gly Gln Thr Ser Thr Leu Ala Asn Val Le - #u Ser Ala Ala Leu Leu       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Leu Phe Trp Gln Gln Cys Gly Trp Leu Al - #a His Asp Phe Leu         His                                                                                              165  - #               170  - #               175              - - His Gln Val Phe Gln Asp Arg Phe Trp Gly As - #p Leu Phe Gly Ala Phe                   180      - #           185      - #           190                   - - Leu Gly Gly Val Cys Gln Gly Phe Ser Ser Se - #r Trp Trp Lys Asp Lys               195          - #       200          - #       205                       - - His Asn Thr His His Ala Ala Pro Asn Val Hi - #s Gly Glu Asp Pro Asp           210              - #   215              - #   220                           - - Ile Asp Thr His Pro Leu Leu Thr Trp Ser Gl - #u His Ala Leu Glu Met       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe Ser Asp Val Pro Asp Glu Glu Leu Thr Ar - #g Met Trp Ser Arg         Phe                                                                                              245  - #               250  - #               255              - - Met Val Leu Asn Gln Thr Trp Phe Tyr Phe Pr - #o Ile Leu Ser Phe Ala                   260      - #           265      - #           270                   - - Arg Leu Ser Trp Cys Leu Gln Ser Ile Leu Ph - #e Val Leu Pro Asn Gly               275          - #       280          - #       285                       - - Gln Ala His Lys Pro Ser Gly Ala Arg Val Pr - #o Ile Ser Leu Val Glu           290              - #   295              - #   300                           - - Gln Leu Ser Leu Ala Met His Trp Thr Trp Ty - #r Leu Ala Thr Met Phe       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Leu Phe Ile Lys Asp Pro Val Asn Met Leu Va - #l Tyr Phe Leu Val         Ser                                                                                              325  - #               330  - #               335              - - Gln Ala Val Cys Gly Asn Leu Leu Ala Ile Va - #l Phe Ser Leu Asn His                   340      - #           345      - #           350                   - - Asn Gly Met Pro Val Ile Ser Lys Glu Glu Al - #a Val Asp Met Asp Phe               355          - #       360          - #       365                       - - Phe Thr Lys Gln Ile Ile Thr Gly Arg Asp Va - #l His Pro Gly Leu Phe           370              - #   375              - #   380                           - - Ala Asn Trp Phe Thr Gly Gly Leu Asn Tyr Gl - #n Ile Glu His His Leu       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Phe Pro Ser Met Pro Arg His Asn Phe Ser Ly - #s Ile Gln Pro Ala         Val                                                                                              405  - #               410  - #               415              - - Glu Thr Leu Cys Lys Lys Tyr Asn Val Arg Ty - #r His Thr Thr Gly Met                   420      - #           425      - #           430                   - - Ile Glu Gly Thr Ala Glu Val Phe Ser Arg Le - #u Asn Glu Val Ser Lys               435          - #       440          - #       445                       - - Ala Ala Ser Lys Met Gly Lys Ala Gln                                           450              - #   455                                                  - -  - - (2) INFORMATION FOR SEQ ID NO:3:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1488 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: DNA (genomic)                                      - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                - - GTCCCCTGTC GCTGTCGGCA CACCCCATCC TCCCTCGCTC CCTCTGCGTT TG -              #TCCTTGGC     60                                                                  - - CCACCGTCTC TCCTCCACCC TCCGAGACGA CTGCAACTGT AATCAGGAAC CG -             #ACAAATAC    120                                                                  - - ACGATTTCTT TTTACTCAGC ACCAACTCAA AATCCTCAAC CGCAACCCTT TT -             #TCAGGATG    180                                                                  - - GCACCTCCCA ACACTATCGA TGCCGGTTTG ACCCAGCGTC ATATCAGCAC CT -             #CGGCCCCA    240                                                                  - - AACTCGGCCA AGCCTGCCTT CGAGCGCAAC TACCAGCTCC CCGAGTTCAC CA -             #TCAAGGAG    300                                                                  - - ATCCGAGAGT GCATCCCTGC CCACTGCTTT GAGCGCTCCG GTCTCCGTGG TC -             #TCTGCCAC    360                                                                  - - GTTGCCATCG ATCTGACTTG GGCGTCGCTC TTGTTCCTGG CTGCGACCCA GA -             #TCGACAAG    420                                                                  - - TTTGAGAATC CCTTGATCCG CTATTTGGCC TGGCCTGTTT ACTGGATCAT GC -             #AGGGTATT    480                                                                  - - GTCTGCACCG GTGTCTGGGT GCTGGCTCAC GAGTGTGGTC ATCAGTCCTT CT -             #CGACCTCC    540                                                                  - - AAGACCCTCA ACAACACAGT TGGTTGGATC TTGCACTCGA TGCTCTTGGT CC -             #CCTACCAC    600                                                                  - - TCCTGGAGAA TCTCGCACTC GAAGCACCAC AAGGCCACTG GCCATATGAC CA -             #AGGACCAG    660                                                                  - - GTCTTTGTGC CCAAGACCCG CTCCCAGGTT GGCTTGCCTC CCAAGGAGAA CG -             #CTGCTGCT    720                                                                  - - GCCGTTCAGG AGGAGGACAT GTCCGTGCAC CTGGATGAGG AGGCTCCCAT TG -             #TGACTTTG    780                                                                  - - TTCTGGATGG TGATCCAGTT CTTGTTCGGA TGGCCCGCGT ACCTGATTAT GA -             #ACGCCTCT    840                                                                  - - GGCCAAGACT ACGGCCGCTG GACCTCGCAC TTCCACACGT ACTCGCCCAT CT -             #TTGAGCCC    900                                                                  - - CGCAACTTTT TCGACATTAT TATCTCGGAC CTCGGTGTGT TGGCTGCCCT CG -             #GTGCCCTG    960                                                                  - - ATCTATGCCT CCATGCAGTT GTCGCTCTTG ACCGTCACCA AGTACTATAT TG -             #TCCCCTAC   1020                                                                  - - CTCTTTGTCA ACTTTTGGTT GGTCCTGATC ACCTTCTTGC AGCACACCGA TC -             #CCAAGCTG   1080                                                                  - - CCCCATTACC GCGAGGGTGC CTGGAATTTC CAGCGTGGAG CTCTTTGCAC CG -             #TTGACCGC   1140                                                                  - - TCGTTTGGCA AGTTCTTGGA CCATATGTTC CACGGCATTG TCCACACCCA TG -             #TGGCCCAT   1200                                                                  - - CACTTGTTCT CGCAAATGCC GTTCTACCAT GCTGAGGAAG CTACCTATCA TC -             #TCAAGAAA   1260                                                                  - - CTGCTGGGAG AGTACTATGT GTACGACCCA TCCCCGATCG TCGTTGCGGT CT -             #GGAGGTCG   1320                                                                  - - TTCCGTGAGT GCCGATTCGT GGAGGATCAG GGAGACGTGG TCTTTTTCAA GA -             #AGTAAAAA   1380                                                                  - - AAAAGACAAT GGACCACACA CAACCTTGTC TCTACAGACC TACGTATCAT GT -             #AGCCATAC   1440                                                                  - - CACTTCATAA AAGAACATGA GCTCTAGAGG CGTGTCATTC GCGCCTCC  - #                   1488                                                                         - -  - - (2) INFORMATION FOR SEQ ID NO:4:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 399 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                - - Met Ala Pro Pro Asn Thr Ile Asp Ala Gly Le - #u Thr Gln Arg His Ile       1               5   - #                10  - #                15                - - Ser Thr Ser Ala Pro Asn Ser Ala Lys Pro Al - #a Phe Glu Arg Asn Tyr                   20      - #            25      - #            30                    - - Gln Leu Pro Glu Phe Thr Ile Lys Glu Ile Ar - #g Glu Cys Ile Pro Ala               35          - #        40          - #        45                        - - His Cys Phe Glu Arg Ser Gly Leu Arg Gly Le - #u Cys His Val Ala Ile           50              - #    55              - #    60                            - - Asp Leu Thr Trp Ala Ser Leu Leu Phe Leu Al - #a Ala Thr Gln Ile Asp       65                  - #70                  - #75                  - #80         - - Lys Phe Glu Asn Pro Leu Ile Arg Tyr Leu Al - #a Trp Pro Val Tyr Trp                       85  - #                90  - #                95                - - Ile Met Gln Gly Ile Val Cys Thr Gly Val Tr - #p Val Leu Ala His Glu                   100      - #           105      - #           110                   - - Cys Gly His Gln Ser Phe Ser Thr Ser Lys Th - #r Leu Asn Asn Thr Val               115          - #       120          - #       125                       - - Gly Trp Ile Leu His Ser Met Leu Leu Val Pr - #o Tyr His Ser Trp Arg           130              - #   135              - #   140                           - - Ile Ser His Ser Lys His His Lys Ala Thr Gl - #y His Met Thr Lys Asp       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gln Val Phe Val Pro Lys Thr Arg Ser Gln Va - #l Gly Leu Pro Pro         Lys                                                                                              165  - #               170  - #               175              - - Glu Asn Ala Ala Ala Ala Val Gln Glu Glu As - #p Met Ser Val His Leu                   180      - #           185      - #           190                   - - Asp Glu Glu Ala Pro Ile Val Thr Leu Phe Tr - #p Met Val Ile Gln Phe               195          - #       200          - #       205                       - - Leu Phe Gly Trp Pro Ala Tyr Leu Ile Met As - #n Ala Ser Gly Gln Asp           210              - #   215              - #   220                           - - Tyr Gly Arg Trp Thr Ser His Phe His Thr Ty - #r Ser Pro Ile Phe Glu       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Pro Arg Asn Phe Phe Asp Ile Ile Ile Ser As - #p Leu Gly Val Leu         Ala                                                                                              245  - #               250  - #               255              - - Ala Leu Gly Ala Leu Ile Tyr Ala Ser Met Gl - #n Leu Ser Leu Leu Thr                   260      - #           265      - #           270                   - - Val Thr Lys Tyr Tyr Ile Val Pro Tyr Leu Ph - #e Val Asn Phe Trp Leu               275          - #       280          - #       285                       - - Val Leu Ile Thr Phe Leu Gln His Thr Asp Pr - #o Lys Leu Pro His Tyr           290              - #   295              - #   300                           - - Arg Glu Gly Ala Trp Asn Phe Gln Arg Gly Al - #a Leu Cys Thr Val Asp       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Arg Ser Phe Gly Lys Phe Leu Asp His Met Ph - #e His Gly Ile Val         His                                                                                              325  - #               330  - #               335              - - Thr His Val Ala His His Leu Phe Ser Gln Me - #t Pro Phe Tyr His Ala                   340      - #           345      - #           350                   - - Glu Glu Ala Thr Tyr His Leu Lys Lys Leu Le - #u Gly Glu Tyr Tyr Val               355          - #       360          - #       365                       - - Tyr Asp Pro Ser Pro Ile Val Val Ala Val Tr - #p Arg Ser Phe Arg Glu           370              - #   375              - #   380                           - - Cys Arg Phe Val Glu Asp Gln Gly Asp Val Va - #l Phe Phe Lys Lys           385                 3 - #90                 3 - #95                             - -  - - (2) INFORMATION FOR SEQ ID NO:5:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 446 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                - - Met Gly Thr Asp Gln Gly Lys Thr Phe Thr Tr - #p Glu Glu Leu Ala Ala       1               5   - #                10  - #                15                - - His Asn Thr Lys Asp Asp Leu Leu Leu Ala Il - #e Arg Gly Arg Val Tyr                   20      - #            25      - #            30                    - - Asp Val Thr Lys Phe Leu Ser Arg His Pro Gl - #y Gly Val Asp Thr Leu               35          - #        40          - #        45                        - - Leu Leu Gly Ala Gly Arg Asp Val Thr Pro Va - #l Phe Glu Met Tyr His           50              - #    55              - #    60                            - - Ala Phe Gly Ala Ala Asp Ala Ile Met Lys Ly - #s Tyr Tyr Val Gly Thr       65                  - #70                  - #75                  - #80         - - Leu Val Ser Asn Glu Leu Pro Ile Phe Pro Gl - #u Pro Thr Val Phe His                       85  - #                90  - #                95                - - Lys Thr Ile Lys Thr Arg Val Glu Gly Tyr Ph - #e Thr Asp Arg Asn Ile                   100      - #           105      - #           110                   - - Asp Pro Lys Asn Arg Pro Glu Ile Trp Gly Ar - #g Tyr Ala Leu Ile Phe               115          - #       120          - #       125                       - - Gly Ser Leu Ile Ala Ser Tyr Tyr Ala Gln Le - #u Phe Val Pro Phe Val           130              - #   135              - #   140                           - - Val Glu Arg Thr Trp Leu Gln Val Val Phe Al - #a Ile Ile Met Gly Phe       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Ala Cys Ala Gln Val Gly Leu Asn Pro Leu Hi - #s Asp Ala Ser His         Phe                                                                                              165  - #               170  - #               175              - - Ser Val Thr His Asn Pro Thr Val Trp Lys Il - #e Leu Gly Ala Thr His                   180      - #           185      - #           190                   - - Asp Phe Phe Asn Gly Ala Ser Tyr Leu Val Tr - #p Met Tyr Gln His Met               195          - #       200          - #       205                       - - Leu Gly His His Pro Tyr Thr Asn Ile Ala Gl - #y Ala Asp Pro Asp Val           210              - #   215              - #   220                           - - Ser Thr Ser Glu Pro Asp Val Arg Arg Ile Ly - #s Pro Asn Gln Lys Trp       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe Val Asn His Ile Asn Gln His Met Phe Va - #l Pro Phe Leu Tyr         Gly                                                                                              245  - #               250  - #               255              - - Leu Leu Ala Phe Lys Val Arg Ile Gln Asp Il - #e Asn Ile Leu Tyr Phe                   260      - #           265      - #           270                   - - Val Lys Thr Asn Asp Ala Ile Arg Val Asn Pr - #o Ile Ser Thr Trp His               275          - #       280          - #       285                       - - Thr Val Met Phe Trp Gly Gly Lys Ala Phe Ph - #e Val Trp Tyr Arg Leu           290              - #   295              - #   300                           - - Ile Val Pro Leu Gln Tyr Leu Pro Leu Gly Ly - #s Val Leu Leu Leu Phe       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Thr Val Ala Asp Met Val Ser Ser Tyr Trp Le - #u Ala Leu Thr Phe         Gln                                                                                              325  - #               330  - #               335              - - Ala Asn His Val Val Glu Glu Val Gln Trp Pr - #o Leu Pro Asp Glu Asn                   340      - #           345      - #           350                   - - Gly Ile Ile Gln Lys Asp Trp Ala Ala Met Gl - #n Val Glu Thr Thr Gln               355          - #       360          - #       365                       - - Asp Tyr Ala His Asp Ser His Leu Trp Thr Se - #r Ile Thr Gly Ser Leu           370              - #   375              - #   380                           - - Asn Tyr Gln Ala Val His His Leu Phe Pro As - #n Val Ser Gln His His       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Tyr Pro Asp Ile Leu Ala Ile Ile Lys Asn Th - #r Cys Ser Glu Tyr         Lys                                                                                              405  - #               410  - #               415              - - Val Pro Tyr Leu Val Lys Asp Thr Phe Trp Gl - #n Ala Phe Ala Ser His                   420      - #           425      - #           430                   - - Leu Glu His Leu Arg Val Leu Gly Leu Arg Pr - #o Lys Glu Glu                       435          - #       440          - #       445                       - -  - - (2) INFORMATION FOR SEQ ID NO:6:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 355 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                - - Glu Val Arg Lys Leu Arg Thr Leu Phe Gln Se - #r Leu Gly Tyr Tyr Asp       1               5   - #                10  - #                15                - - Ser Ser Lys Ala Tyr Tyr Ala Phe Lys Val Se - #r Phe Asn Leu Cys Ile                   20      - #            25      - #            30                    - - Trp Gly Leu Ser Thr Val Ile Val Ala Lys Tr - #p Gly Gln Thr Ser Thr               35          - #        40          - #        45                        - - Leu Ala Asn Val Leu Ser Ala Ala Leu Leu Gl - #y Leu Phe Trp Gln Gln           50              - #    55              - #    60                            - - Cys Gly Trp Leu Ala His Asp Phe Leu His Hi - #s Gln Val Phe Gln Asp       65                  - #70                  - #75                  - #80         - - Arg Phe Trp Gly Asp Leu Phe Gly Ala Phe Le - #u Gly Gly Val Cys Gln                       85  - #                90  - #                95                - - Gly Phe Ser Ser Ser Trp Trp Lys Asp Lys Hi - #s Asn Thr His His Ala                   100      - #           105      - #           110                   - - Ala Pro Asn Val His Gly Glu Asp Pro Asp Il - #e Asp Thr His Pro Leu               115          - #       120          - #       125                       - - Leu Thr Trp Ser Glu His Ala Leu Glu Met Ph - #e Ser Asp Val Pro Asp           130              - #   135              - #   140                           - - Glu Glu Leu Thr Arg Met Trp Ser Arg Phe Me - #t Val Leu Asn Gln Thr       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Trp Phe Tyr Phe Pro Ile Leu Ser Phe Ala Ar - #g Leu Ser Trp Cys         Leu                                                                                              165  - #               170  - #               175              - - Gln Ser Ile Leu Phe Val Leu Pro Asn Gly Gl - #n Ala His Lys Pro Ser                   180      - #           185      - #           190                   - - Gly Ala Arg Val Pro Ile Ser Leu Val Glu Gl - #n Leu Ser Leu Ala Met               195          - #       200          - #       205                       - - His Trp Thr Trp Tyr Leu Ala Thr Met Phe Le - #u Phe Ile Lys Asp Pro           210              - #   215              - #   220                           - - Val Asn Met Leu Val Tyr Phe Leu Val Ser Gl - #n Ala Val Cys Gly Asn       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Leu Leu Ala Ile Val Phe Ser Leu Asn His As - #n Gly Met Pro Val         Ile                                                                                              245  - #               250  - #               255              - - Ser Lys Glu Glu Ala Val Asp Met Asp Phe Ph - #e Thr Lys Gln Ile Ile                   260      - #           265      - #           270                   - - Thr Gly Arg Asp Val His Pro Gly Leu Phe Al - #a Asn Trp Phe Thr Gly               275          - #       280          - #       285                       - - Gly Leu Asn Tyr Gln Ile Glu His His Leu Ph - #e Pro Ser Met Pro Arg           290              - #   295              - #   300                           - - His Asn Phe Ser Lys Ile Gln Pro Ala Val Gl - #u Thr Leu Cys Lys Lys       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Tyr Asn Val Arg Tyr His Thr Thr Gly Met Il - #e Glu Gly Thr Ala         Glu                                                                                              325  - #               330  - #               335              - - Val Phe Ser Arg Leu Asn Glu Val Ser Lys Al - #a Ala Ser Lys Met Gly                   340      - #           345      - #           350                   - - Lys Ala Gln                                                                       355                                                                     - -  - - (2) INFORMATION FOR SEQ ID NO:7:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 104 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                - - Val Thr Leu Tyr Thr Leu Ala Phe Val Ala Al - #a Asn Ser Leu Gly Val       1               5   - #                10  - #                15                - - Leu Tyr Gly Val Leu Ala Cys Pro Ser Val Xa - #a Pro His Gln Ile Ala                   20      - #            25      - #            30                    - - Ala Gly Leu Leu Gly Leu Leu Trp Ile Gln Se - #r Ala Tyr Ile Gly Xaa               35          - #        40          - #        45                        - - Asp Ser Gly His Tyr Val Ile Met Ser Asn Ly - #s Ser Asn Asn Xaa Phe           50              - #    55              - #    60                            - - Ala Gln Leu Leu Ser Gly Asn Cys Leu Thr Gl - #y Ile Ile Ala Trp Trp       65                  - #70                  - #75                  - #80         - - Lys Trp Thr His Asn Ala His His Leu Ala Cy - #s Asn Ser Leu Asp Tyr                       85  - #                90  - #                95                - - Gly Pro Asn Leu Gln His Ile Pro                                                       100                                                                 - -  - - (2) INFORMATION FOR SEQ ID NO:8:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 252 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                - - Gly Val Leu Tyr Gly Val Leu Ala Cys Thr Se - #r Val Phe Ala His Gln       1               5   - #                10  - #                15                - - Ile Ala Ala Ala Leu Leu Gly Leu Leu Trp Il - #e Gln Ser Ala Tyr Ile                   20      - #            25      - #            30                    - - Gly His Asp Ser Gly His Tyr Val Ile Met Se - #r Asn Lys Ser Tyr Asn               35          - #        40          - #        45                        - - Arg Phe Ala Gln Leu Leu Ser Gly Asn Cys Le - #u Thr Gly Ile Ser Ile           50              - #    55              - #    60                            - - Ala Trp Trp Lys Trp Thr His Asn Ala His Hi - #s Leu Ala Cys Asn Ser       65                  - #70                  - #75                  - #80         - - Leu Asp Tyr Asp Pro Asp Leu Gln His Ile Pr - #o Val Phe Ala Val Ser                       85  - #                90  - #                95                - - Thr Lys Phe Phe Ser Ser Leu Thr Ser Arg Ph - #e Tyr Asp Arg Lys Leu                   100      - #           105      - #           110                   - - Thr Phe Gly Pro Val Ala Arg Phe Leu Val Se - #r Tyr Gln His Phe Thr               115          - #       120          - #       125                       - - Tyr Tyr Pro Val Asn Cys Phe Gly Arg Ile As - #n Leu Phe Ile Gln Thr           130              - #   135              - #   140                           - - Phe Leu Leu Leu Phe Ser Lys Arg Glu Val Pr - #o Asp Arg Ala Leu Asn       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Phe Ala Gly Ile Leu Val Phe Trp Thr Trp Ph - #e Pro Leu Leu Val         Ser                                                                                              165  - #               170  - #               175              - - Cys Leu Pro Asn Trp Pro Glu Arg Phe Phe Ph - #e Val Phe Thr Ser Phe                   180      - #           185      - #           190                   - - Thr Val Thr Ala Leu Gln His Ile Gln Phe Th - #r Leu Asn His Phe Ala               195          - #       200          - #       205                       - - Ala Asp Val Tyr Val Gly Pro Pro Thr Gly Se - #r Asp Trp Phe Glu Lys           210              - #   215              - #   220                           - - Gln Ala Ala Gly Thr Ile Asp Ile Ser Cys Ar - #g Ser Tyr Met Asp Trp       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe Phe Gly Gly Leu Gln Phe Gln Leu Glu Hi - #s His                                       245  - #               250                                      - -  - - (2) INFORMATION FOR SEQ ID NO:9:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 125 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                - - Gly Xaa Xaa Asn Phe Ala Gly Ile Leu Val Ph - #e Trp Thr Trp Phe         Pro                                                                              1               5   - #                10  - #                15               - - Leu Leu Val Ser Cys Leu Pro Asn Trp Pro Gl - #u Arg Phe Xaa Phe Val                   20      - #            25      - #            30                    - - Phe Thr Gly Phe Thr Val Thr Ala Leu Gln Hi - #s Ile Gln Phe Thr Leu               35          - #        40          - #        45                        - - Asn His Phe Ala Ala Asp Val Tyr Val Gly Pr - #o Pro Thr Gly Ser Asp           50              - #    55              - #    60                            - - Trp Phe Glu Lys Gln Ala Ala Gly Thr Ile As - #p Ile Ser Cys Arg Ser       65                  - #70                  - #75                  - #80         - - Tyr Met Asp Trp Phe Phe Cys Gly Leu Gln Ph - #e Gln Leu Glu His His                       85  - #                90  - #                95                - - Leu Phe Pro Arg Leu Pro Arg Cys His Leu Ar - #g Lys Val Ser Pro Val                   100      - #           105      - #           110                   - - Gly Gln Arg Gly Phe Gln Arg Lys Xaa Asn Le - #u Ser Xaa                           115          - #       120          - #       125                       - -  - - (2) INFORMATION FOR SEQ ID NO:10:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 131 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                               - - Pro Ala Thr Glu Val Gly Gly Leu Ala Trp Me - #t Ile Thr Phe Tyr Val       1               5   - #                10  - #                15                - - Arg Phe Phe Leu Thr Tyr Val Pro Leu Leu Gl - #y Leu Lys Ala Phe Leu                   20      - #            25      - #            30                    - - Gly Leu Phe Phe Ile Val Arg Phe Leu Glu Se - #r Asn Trp Phe Val Trp               35          - #        40          - #        45                        - - Val Thr Gln Met Asn His Ile Pro Met His Il - #e Asp His Asp Arg Asn           50              - #    55              - #    60                            - - Met Asp Trp Val Ser Thr Gln Leu Gln Ala Th - #r Cys Asn Val His Lys       65                  - #70                  - #75                  - #80         - - Ser Ala Phe Asn Asp Trp Phe Ser Gly His Le - #u Asn Phe Gln Ile Glu                       85  - #                90  - #                95                - - His His Leu Phe Pro Thr Met Pro Arg His As - #n Tyr His Xaa Val Ala                   100      - #           105      - #           110                   - - Pro Leu Val Gln Ser Leu Cys Ala Lys His Gl - #y Ile Glu Tyr Gln Ser               115          - #       120          - #       125                       - - Lys Pro Leu                                                                   130                                                                         - -  - - (2) INFORMATION FOR SEQ ID NO:11:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 87 amino - #acids                                                  (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:                               - - Cys Ser Pro Lys Ser Ser Pro Thr Arg Asn Me - #t Thr Pro Ser Pro Phe       1               5   - #                10  - #                15                - - Ile Asp Trp Leu Trp Gly Gly Leu Asn Tyr Gl - #n Ile Glu His His Leu                   20      - #            25      - #            30                    - - Phe Pro Thr Met Pro Arg Cys Asn Leu Asn Ar - #g Cys Met Lys Tyr Val               35          - #        40          - #        45                        - - Lys Glu Trp Cys Ala Glu Asn Asn Leu Pro Ty - #r Leu Val Asp Asp Tyr           50              - #    55              - #    60                            - - Phe Val Gly Tyr Asn Leu Asn Leu Gln Gln Le - #u Lys Asn Met Ala Glu       65                  - #70                  - #75                  - #80         - - Leu Val Gln Ala Lys Ala Ala                                                               85                                                              - -  - - (2) INFORMATION FOR SEQ ID NO:12:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 143 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:                               - - Arg His Glu Ala Ala Arg Gly Gly Thr Arg Le - #u Ala Tyr Met Leu Val       1               5   - #                10  - #                15                - - Cys Met Gln Trp Thr Asp Leu Leu Trp Ala Al - #a Ser Phe Tyr Ser Arg                   20      - #            25      - #            30                    - - Phe Phe Leu Ser Tyr Ser Pro Phe Tyr Gly Al - #a Thr Gly Thr Leu Leu               35          - #        40          - #        45                        - - Leu Phe Val Ala Val Arg Val Leu Glu Ser Hi - #s Trp Phe Val Trp Ile           50              - #    55              - #    60                            - - Thr Gln Met Asn His Ile Pro Lys Glu Ile Gl - #y His Glu Lys His Arg       65                  - #70                  - #75                  - #80         - - Asp Trp Ala Ser Ser Gln Leu Ala Ala Thr Cy - #s Asn Val Glu Pro Ser                       85  - #                90  - #                95                - - Leu Phe Ile Asp Trp Phe Ser Gly His Leu As - #n Phe Gln Ile Glu His                   100      - #           105      - #           110                   - - His Leu Phe Pro Thr Met Thr Arg His Asn Ty - #r Arg Xaa Val Ala Pro               115          - #       120          - #       125                       - - Leu Val Lys Ala Phe Cys Ala Lys His Gly Le - #u His Tyr Glu Val               130              - #   135              - #   140                           - -  - - (2) INFORMATION FOR SEQ ID NO:13:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 186 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:                               - - Leu His His Thr Tyr Thr Asn Ile Ala Gly Al - #a Asp Pro Asp Val Ser       1               5   - #                10  - #                15                - - Thr Ser Glu Pro Asp Val Arg Arg Ile Lys Pr - #o Asn Gln Lys Trp Phe                   20      - #            25      - #            30                    - - Val Asn His Ile Asn Gln His Met Phe Val Pr - #o Phe Leu Tyr Gly Leu               35          - #        40          - #        45                        - - Leu Ala Phe Lys Val Arg Ile Gln Asp Ile As - #n Ile Leu Tyr Phe Val           50              - #    55              - #    60                            - - Lys Thr Asn Asp Ala Ile Arg Val Asn Pro Il - #e Ser Thr Trp His Thr       65                  - #70                  - #75                  - #80         - - Val Met Phe Trp Gly Gly Lys Ala Phe Phe Va - #l Trp Tyr Arg Leu Ile                       85  - #                90  - #                95                - - Val Pro Leu Gln Tyr Leu Pro Leu Gly Lys Va - #l Leu Leu Leu Phe Thr                   100      - #           105      - #           110                   - - Val Ala Asp Met Val Ser Ser Tyr Trp Leu Al - #a Leu Thr Phe Gln Ala               115          - #       120          - #       125                       - - Asn Tyr Val Val Glu Glu Val Gln Trp Pro Le - #u Pro Asp Glu Asn Gly           130              - #   135              - #   140                           - - Ile Ile Gln Lys Asp Trp Ala Ala Met Gln Va - #l Glu Thr Thr Gln Asp       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Tyr Ala His Asp Ser His Leu Trp Thr Ser Il - #e Thr Gly Ser Leu         Asn                                                                                              165  - #               170  - #               175              - - Tyr Gln Xaa Val His His Leu Phe Pro His                                               180      - #           185                                          - -  - - (2) INFORMATION FOR SEQ ID NO:14:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 457 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:                               - - Met Ala Ala Ala Pro Ser Val Arg Thr Phe Th - #r Arg Ala Glu Val Leu       1               5   - #                10  - #                15                - - Asn Ala Glu Ala Leu Asn Glu Gly Lys Lys As - #p Ala Glu Ala Pro Phe                   20      - #            25      - #            30                    - - Leu Met Ile Ile Asp Asn Lys Val Tyr Asp Va - #l Arg Glu Phe Val Pro               35          - #        40          - #        45                        - - Asp His Pro Gly Gly Ser Val Ile Leu Thr Hi - #s Val Gly Lys Asp Gly           50              - #    55              - #    60                            - - Thr Asp Val Phe Asp Thr Phe His Pro Glu Al - #a Ala Trp Glu Thr Leu       65                  - #70                  - #75                  - #80         - - Ala Asn Phe Tyr Val Gly Asp Ile Asp Glu Se - #r Asp Arg Asp Ile Lys                       85  - #                90  - #                95                - - Asn Asp Asp Phe Ala Ala Glu Val Arg Lys Le - #u Arg Thr Leu Phe Gln                   100      - #           105      - #           110                   - - Ser Leu Gly Tyr Tyr Asp Ser Ser Lys Ala Ty - #r Tyr Ala Phe Lys Val               115          - #       120          - #       125                       - - Ser Phe Asn Leu Cys Ile Trp Gly Leu Ser Th - #r Val Ile Val Ala Lys           130              - #   135              - #   140                           - - Trp Gly Gln Thr Ser Thr Leu Ala Asn Val Le - #u Ser Ala Ala Leu Leu       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Leu Phe Trp Gln Gln Cys Gly Trp Leu Al - #a His Asp Phe Leu         His                                                                                              165  - #               170  - #               175              - - His Gln Val Phe Gln Asp Arg Phe Trp Gly As - #p Leu Phe Gly Ala Phe                   180      - #           185      - #           190                   - - Leu Gly Gly Val Cys Gln Gly Phe Ser Ser Se - #r Trp Trp Lys Asp Lys               195          - #       200          - #       205                       - - His Asn Thr His His Ala Ala Pro Asn Val Hi - #s Val Glu Asp Pro Asp           210              - #   215              - #   220                           - - Ile Asp Thr His Pro Leu Leu Thr Trp Ser Gl - #u His Ala Leu Glu Met       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe Ser Asp Val Pro Asp Glu Glu Leu Thr Ar - #g Met Trp Ser Arg         Phe                                                                                              245  - #               250  - #               255              - - Met Val Leu Asn Gln Thr Trp Phe Tyr Phe Pr - #o Ile Leu Ser Phe Ala                   260      - #           265      - #           270                   - - Arg Leu Ser Trp Cys Leu Gln Ser Ile Leu Ph - #e Val Leu Pro Asn Gly               275          - #       280          - #       285                       - - Gln Ala His Lys Pro Ser Gly Ala Arg Val Pr - #o Ile Ser Leu Val Glu           290              - #   295              - #   300                           - - Gln Leu Ser Leu Ala Met His Trp Thr Trp Ty - #r Leu Ala Thr Met Phe       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Leu Phe Ile Lys Asp Pro Val Asn Met Leu Va - #l Tyr Phe Leu Val         Ser                                                                                              325  - #               330  - #               335              - - Gln Ala Val Cys Gly Asn Leu Leu Ala Ile Va - #l Phe Ser Leu Asn His                   340      - #           345      - #           350                   - - Asn Gly Met Pro Val Ile Ser Lys Glu Glu Al - #a Val Asp Met Asp Phe               355          - #       360          - #       365                       - - Phe Thr Lys Gln Ile Ile Thr Gly Arg Asp Va - #l His Pro Gly Leu Phe           370              - #   375              - #   380                           - - Ala Asn Trp Phe Thr Gly Gly Leu Asn Tyr Gl - #n Ile Glu His His Leu       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Phe Pro Ser Met Pro Arg His Asn Phe Ser Ly - #s Ile Gln Pro Ala         Val                                                                                              405  - #               410  - #               415              - - Glu Thr Leu Cys Lys Lys Tyr Asn Val Arg Ty - #r His Thr Thr Gly Met                   420      - #           425      - #           430                   - - Ile Glu Gly Thr Ala Glu Val Phe Ser Arg Le - #u Asn Glu Val Ser Lys               435          - #       440          - #       445                       - - Ala Ala Ser Lys Met Gly Lys Ala Gln                                           450              - #   455                                                  - -  - - (2) INFORMATION FOR SEQ ID NO:15:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 446 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:                               - - Met Ala Ala Gln Ile Lys Lys Tyr Ile Thr Se - #r Asp Glu Leu Lys Asn       1               5   - #                10  - #                15                - - His Asp Lys Pro Gly Asp Leu Trp Ile Ser Il - #e Gln Gly Lys Ala Tyr                   20      - #            25      - #            30                    - - Asp Val Ser Asp Trp Val Lys Asp His Pro Gl - #y Gly Ser Phe Pro Leu               35          - #        40          - #        45                        - - Lys Ser Leu Ala Gly Gln Glu Val Thr Asp Al - #a Phe Val Ala Phe His           50              - #    55              - #    60                            - - Pro Ala Ser Thr Trp Lys Asn Leu Asp Lys Ph - #e Phe Thr Gly Tyr Tyr       65                  - #70                  - #75                  - #80         - - Leu Lys Asp Tyr Ser Val Ser Glu Val Ser Ly - #s Val Tyr Arg Lys Leu                       85  - #                90  - #                95                - - Val Phe Glu Phe Ser Lys Met Gly Leu Tyr As - #p Lys Lys Gly His Ile                   100      - #           105      - #           110                   - - Met Phe Ala Thr Leu Cys Phe Ile Ala Met Le - #u Phe Ala Met Ser Val               115          - #       120          - #       125                       - - Tyr Gly Val Leu Phe Cys Glu Gly Val Leu Va - #l His Leu Phe Ser Gly           130              - #   135              - #   140                           - - Cys Leu Met Gly Phe Leu Trp Ile Gln Ser Gl - #y Trp Ile Gly His Asp       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Ala Gly His Tyr Met Val Val Ser Asp Ser Ar - #g Leu Asn Lys Phe         Met                                                                                              165  - #               170  - #               175              - - Gly Ile Phe Ala Ala Asn Cys Leu Ser Gly Il - #e Ser Ile Gly Trp Trp                   180      - #           185      - #           190                   - - Lys Trp Asn His Asn Ala His His Ile Ala Cy - #s Asn Ser Leu Glu Tyr               195          - #       200          - #       205                       - - Asp Pro Asp Leu Gln Tyr Ile Pro Phe Leu Va - #l Val Ser Ser Lys Phe           210              - #   215              - #   220                           - - Phe Gly Ser Leu Thr Ser His Phe Tyr Glu Ly - #s Arg Leu Thr Phe Asp       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Ser Leu Ser Arg Phe Phe Val Ser Tyr Gln Hi - #s Trp Thr Phe Tyr         Pro                                                                                              245  - #               250  - #               255              - - Ile Met Cys Ala Ala Arg Leu Asn Met Tyr Va - #l Gln Ser Leu Ile Met                   260      - #           265      - #           270                   - - Leu Leu Thr Lys Arg Asn Val Ser Tyr Arg Al - #a Gln Glu Leu Leu Gly               275          - #       280          - #       285                       - - Cys Leu Val Phe Ser Ile Trp Tyr Pro Leu Le - #u Val Ser Cys Leu Pro           290              - #   295              - #   300                           - - Asn Trp Gly Glu Arg Ile Met Phe Val Ile Al - #a Ser Leu Ser Val Thr       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Gly Met Gln Gln Val Gln Phe Ser Leu Asn Hi - #s Phe Ser Ser Ser         Val                                                                                              325  - #               330  - #               335              - - Tyr Val Gly Lys Pro Lys Gly Asn Asn Trp Ph - #e Glu Lys Gln Thr Asp                   340      - #           345      - #           350                   - - Gly Thr Leu Asp Ile Ser Cys Pro Pro Trp Me - #t Asp Trp Phe His Gly               355          - #       360          - #       365                       - - Gly Leu Gln Phe Gln Ile Glu His His Leu Ph - #e Pro Lys Met Pro Arg           370              - #   375              - #   380                           - - Cys Asn Leu Arg Lys Ile Ser Pro Tyr Val Il - #e Glu Leu Cys Lys Lys       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - His Asn Leu Pro Tyr Asn Tyr Ala Ser Phe Se - #r Lys Ala Asn Glu         Met                                                                                              405  - #               410  - #               415              - - Thr Leu Arg Thr Leu Arg Asn Thr Ala Leu Gl - #n Ala Arg Asp Ile Thr                   420      - #           425      - #           430                   - - Lys Pro Leu Pro Lys Asn Leu Val Trp Glu Al - #a Leu His Thr                       435          - #       440          - #       445                       - -  - - (2) INFORMATION FOR SEQ ID NO:16:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 359 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:                               - - Met Leu Thr Ala Glu Arg Ile Lys Phe Thr Gl - #n Lys Arg Gly Phe Arg       1               5   - #                10  - #                15                - - Arg Val Leu Asn Gln Arg Val Asp Ala Tyr Ph - #e Ala Glu His Gly Leu                   20      - #            25      - #            30                    - - Thr Gln Arg Asp Asn Pro Ser Met Tyr Leu Ly - #s Thr Leu Ile Ile Val               35          - #        40          - #        45                        - - Leu Trp Leu Phe Ser Ala Trp Ala Phe Val Le - #u Phe Ala Pro Val Ile           50              - #    55              - #    60                            - - Phe Pro Val Arg Leu Leu Gly Cys Met Val Le - #u Ala Ile Ala Leu Ala       65                  - #70                  - #75                  - #80         - - Ala Phe Ser Phe Asn Val Gly His Asp Ala As - #n His Asn Ala Tyr Ser                       85  - #                90  - #                95                - - Ser Asn Pro His Ile Asn Arg Val Leu Gly Me - #t Thr Tyr Asp Phe Val                   100      - #           105      - #           110                   - - Gly Leu Ser Ser Phe Leu Trp Arg Tyr Arg Hi - #s Asn Tyr Leu His His               115          - #       120          - #       125                       - - Thr Tyr Thr Asn Ile Leu Gly His Asp Val Gl - #u Ile His Gly Asp Gly           130              - #   135              - #   140                           - - Ala Val Arg Met Ser Pro Glu Gln Glu His Va - #l Gly Ile Tyr Arg Phe       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gln Gln Phe Tyr Ile Trp Gly Leu Tyr Leu Ph - #e Ile Pro Phe Tyr         Trp                                                                                              165  - #               170  - #               175              - - Phe Leu Tyr Asp Val Tyr Leu Val Leu Asn Ly - #s Gly Lys Tyr His Asp                   180      - #           185      - #           190                   - - His Lys Ile Pro Pro Phe Gln Pro Leu Glu Le - #u Ala Ser Leu Leu Gly               195          - #       200          - #       205                       - - Ile Lys Leu Leu Trp Leu Gly Tyr Val Phe Gl - #y Leu Pro Leu Ala Leu           210              - #   215              - #   220                           - - Gly Phe Ser Ile Pro Glu Val Leu Ile Gly Al - #a Ser Val Thr Tyr Met       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Thr Tyr Gly Ile Val Val Cys Thr Ile Phe Me - #t Leu Ala His Val         Leu                                                                                              245  - #               250  - #               255              - - Glu Ser Thr Glu Phe Leu Thr Pro Asp Gly Gl - #u Ser Gly Ala Ile Asp                   260      - #           265      - #           270                   - - Asp Glu Trp Ala Ile Cys Gln Ile Arg Thr Th - #r Ala Asn Phe Ala Thr               275          - #       280          - #       285                       - - Asn Asn Pro Phe Trp Asn Trp Phe Cys Gly Gl - #y Leu Asn His Gln Val           290              - #   295              - #   300                           - - Thr His His Leu Phe Pro Asn Ile Cys His Il - #e His Tyr Pro Gln Leu       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Glu Asn Ile Ile Lys Asp Val Cys Gln Glu Ph - #e Gly Val Glu Tyr         Lys                                                                                              325  - #               330  - #               335              - - Val Tyr Pro Thr Phe Lys Ala Ala Ile Ala Se - #r Asn Tyr Arg Trp Leu                   340      - #           345      - #           350                   - - Glu Ala Met Gly Lys Ala Ser                                                       355                                                                     - -  - - (2) INFORMATION FOR SEQ ID NO:17:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 365 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:                               - - Met Thr Ser Thr Thr Ser Lys Val Thr Phe Gl - #y Lys Ser Ile Gly Phe       1               5   - #                10  - #                15                - - Arg Lys Glu Leu Asn Arg Arg Val Asn Ala Ty - #r Leu Glu Ala Glu Asn                   20      - #            25      - #            30                    - - Ile Ser Pro Arg Asp Asn Pro Pro Met Tyr Le - #u Lys Thr Ala Ile Ile               35          - #        40          - #        45                        - - Leu Ala Trp Val Val Ser Ala Trp Thr Phe Va - #l Val Phe Gly Pro Asp           50              - #    55              - #    60                            - - Val Leu Trp Met Lys Leu Leu Gly Cys Ile Va - #l Leu Gly Phe Gly Val       65                  - #70                  - #75                  - #80         - - Ser Ala Val Gly Phe Asn Ile Ser His Asp Gl - #y Asn His Gly Gly Tyr                       85  - #                90  - #                95                - - Ser Lys Tyr Gln Trp Val Asn Tyr Leu Ser Gl - #y Leu Thr His Asp Ala                   100      - #           105      - #           110                   - - Ile Gly Val Ser Ser Tyr Leu Trp Lys Phe Ar - #g His Asn Val Leu His               115          - #       120          - #       125                       - - His Thr Tyr Thr Asn Ile Leu Gly His Asp Va - #l Glu Ile His Gly Asp           130              - #   135              - #   140                           - - Glu Leu Val Arg Met Ser Pro Ser Met Glu Ty - #r Arg Trp Tyr His Arg       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Tyr Gln His Trp Phe Ile Trp Phe Val Tyr Pr - #o Phe Ile Pro Tyr         Tyr                                                                                              165  - #               170  - #               175              - - Trp Ser Ile Ala Asp Val Gln Thr Met Leu Ph - #e Lys Arg Gln Tyr His                   180      - #           185      - #           190                   - - Asp His Glu Ile Pro Ser Pro Thr Trp Val As - #p Ile Ala Thr Leu Leu               195          - #       200          - #       205                       - - Ala Phe Lys Ala Phe Gly Val Ala Val Phe Le - #u Ile Ile Pro Ile Ala           210              - #   215              - #   220                           - - Val Gly Tyr Ser Pro Leu Glu Ala Val Ile Gl - #y Ala Ser Ile Val Tyr       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Met Thr His Gly Leu Val Ala Cys Val Val Ph - #e Met Leu Ala His         Val                                                                                              245  - #               250  - #               255              - - Ile Glu Pro Ala Glu Phe Leu Asp Pro Asp As - #n Leu His Ile Asp Asp                   260      - #           265      - #           270                   - - Glu Trp Ala Ile Ala Gln Val Lys Thr Thr Va - #l Asp Phe Ala Pro Asn               275          - #       280          - #       285                       - - Asn Thr Ile Ile Asn Trp Tyr Val Gly Gly Le - #u Asn Tyr Gln Thr Val           290              - #   295              - #   300                           - - His His Leu Phe Pro His Ile Cys His Ile Hi - #s Tyr Pro Lys Ile Ala       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Pro Ile Leu Ala Glu Val Cys Glu Glu Phe Gl - #y Val Asn Tyr Ala         Val                                                                                              325  - #               330  - #               335              - - His Gln Thr Phe Phe Gly Ala Leu Ala Ala As - #n Tyr Ser Trp Leu Lys                   340      - #           345      - #           350                   - - Lys Met Ser Ile Asn Pro Glu Thr Lys Ala Il - #e Glu Gln                           355          - #       360          - #       365                       - -  - - (2) INFORMATION FOR SEQ ID NO:18:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 35 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:                               - - CCAAGCTTCT GCAGGAGCTC TTTTTTTTTT TTTTT       - #                  -      #       35                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:19:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 32 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (ix) FEATURE:                                                                   (A) OTHER INFORMATION: - #N is equivalent to Inosine or             Cytosine                                                                          - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:                               - - CUACUACUAC UACAYCAYAC NTAYACNAAY AT       - #                  - #               32                                                                      - -  - - (2) INFORMATION FOR SEQ ID NO:20:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 27 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (ix) FEATURE:                                                                   (A) OTHER INFORMATION: - #N is equivalent to Inosine or             Cytosine                                                                          - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:                               - - CAUCAUCAUC AUNGGRAANA RRTGRTG          - #                  - #                  27                                                                      - -  - - (2) INFORMATION FOR SEQ ID NO:21:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 33 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:                               - - CUACUACUAC UAGGAGTCCT CTACGGTGTT TTG       - #                  - #              33                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:22:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 33 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:                               - - CAUCAUCAUC AUATGATGCT CAAGCTGAAA CTG       - #                  - #              33                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:23:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 39 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:                               - - CUACUACUAC UACTCGAGCA AGATGGGAAC GGACCAAGG      - #                       - #    39                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:24:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 39 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:                               - - CAUCAUCAUC AUCTCGAGCT ACTCTTCCTT GGGACGGAG      - #                       - #    39                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:25:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 47 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:                               - - CUACUACUAC UATCTAGACT CGAGACCATG GCTGCTGCTC CAGTGTG   - #                     47                                                                          - -  - - (2) INFORMATION FOR SEQ ID NO:26:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 40 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:                               - - CAUCAUCAUC AUAGGCCTCG AGTTACTGCG CCTTACCCAT     - #                       - #    40                                                                     __________________________________________________________________________ 

What is claimed is:
 1. A nucleic acid construct comprising one or more nucleotide sequences depicted in a SEQ ID NO: selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3 linked to a heterologous nucleotide sequence.
 2. A nucleic acid construct comprising one or more nucleotide sequences depicted in a SEQ ID NO: selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3 operably associated with an expression control sequence in a plant cell.
 3. The nucleic acid construct according to claim 2, wherein said nucleotide sequence is derived from a fungus.
 4. The nucleic acid construct according to claim 3, wherein said fungus is of the genus Mortierella.
 5. The nucleic acid construct according to claim 4, wherein said fungus is of the species alpina.
 6. A nucleic acid construct comprising a nucleotide sequence which encodes a polypeptide comprising the amino acid sequence depicted in SEQ ID NO:2, wherein said nucleotide sequence is operably associated with a transcription or an expression control sequence functional in a plant cell, wherein said nucleotide sequence encodes a functionally active polypeptide which removes hydrogen atoms from carbons 6 and 7 as numbered from the carboxy terminus of a fatty acid molecule to form an unsaturated bond.
 7. A nucleic acid construct comprising a nucleotide sequence which encodes a polypeptide comprising the amino acid sequence depicted in SEQ ID NO:4, wherein said nucleotide sequence is operably associated with a transcription or an expression control sequence functional in a plant cell, wherein said nucleotide sequence encodes a functionally active polypeptide which removes hydrogen atoms from carbons 5 and 6 as numbered from the carboxy terminus of a fatty acid molecule to form an unsaturated bond.
 8. A nucleic acid construct comprising a nucleotide sequence which encodes a functionally active desaturase having the amino acid sequence depicted in a SEQ ID NO: selected from the group consisting of SEQ ID NO:4, and SEQ ID NO:2, wherein said nucleotide sequence is operably associated with a promoter functional in a plant cell.
 9. The nucleic acid construct according to claim 8, wherein said plant cell is a seed cell.
 10. The nucleic acid construct according to claim 9, wherein said seed cell is an embryo cell.
 11. A microbial or plant host cell comprising at least one copy of a DNA sequence which encodes at least one functionally active Mortierella alpina fatty acid desaturase having an amino acid sequence as depicted in SEQ NO: selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4, wherein said cell or parent of said cell was transformed with a vector comprising said DNA sequence, and wherein said DNA sequence is operably associated with an expression control sequence.
 12. The recombinant host cell of claim 11, wherein said host cell is a plant cell.
 13. The nucleic acid construct of claim 8, wherein said amino acid sequence is derived from the genus Mortierella.
 14. An isolated or purified polynucleotide comprising the nucleotide sequence depicted in SEQ ID NO: 1 or SEQ ID NO:
 3. 15. An isolated or purified nucleotide sequence encoding the polypeptide depicted in SEQ ID NO: 2 or SEQ ID NO:
 4. 16. The host cell according to claim 12, wherein said host cell is a plant cell enriched in 18:1 or 18:2 fatty acids after said cell has been transformed with said vector.
 17. The host cell according to claim 16, wherein said plant cell is from a plant selected from the group consisting of Brassica, soybean, safflower, and sunflower.
 18. The host cell according to claim 12, wherein said expression control sequence is endogenous to said plant cell.
 19. A method for obtaining altered long chain polyunsaturated fatty acid biosynthesis in a plant, said method comprising growing a plant having cells which contain one or more transgenes encoding a transgene expression product having an amino acid sequence depicted in a SEQ ID NO: selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:2 which desaturates a fatty acid molecule at carbon 6 or carbon 12 from the carboxyl end of said fatty acid molecule, wherein said one or more transgenes is operably associated with an expression control sequence, under conditions whereby said one or more transgenes is expressed, whereby long chain polyunsaturated fatty acid biosynthesis in said cells is altered.
 20. The method according to claim 19, wherein said one or more transgenes is derived from Mortierella alpina.
 21. The method according to claim 19, wherein said long chain polyunsaturated fatty acid is arachidonic acid.
 22. The host cell according to claim 12, wherein said plant cell which is enriched in 18:3 or 18:4 fatty acids after said cell has been transformed with said vector. 